<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10221052</article-id><article-id pub-id-type="doi">10.3390/molecules28104183</article-id><article-id pub-id-type="publisher-id">molecules-28-04183</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Combating Antimicrobial Resistance in the Post-Genomic Era: Rapid Antibiotic Discovery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yuehan</given-names></name><xref rid="af1-molecules-28-04183" ref-type="aff">1</xref><xref rid="af2-molecules-28-04183" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kessler</surname><given-names>Mara Grace C.</given-names></name><xref rid="af2-molecules-28-04183" ref-type="aff">2</xref><xref rid="af3-molecules-28-04183" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2495-1703</contrib-id><name><surname>March&#x000e1;n-Rivadeneira</surname><given-names>Maria Raquel</given-names></name><xref rid="af1-molecules-28-04183" ref-type="aff">1</xref><xref rid="af2-molecules-28-04183" ref-type="aff">2</xref><xref rid="af4-molecules-28-04183" ref-type="aff">4</xref><xref rid="af5-molecules-28-04183" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3833-1473</contrib-id><name><surname>Han</surname><given-names>Yong</given-names></name><xref rid="af1-molecules-28-04183" ref-type="aff">1</xref><xref rid="af2-molecules-28-04183" ref-type="aff">2</xref><xref rid="af6-molecules-28-04183" ref-type="aff">6</xref><xref rid="c1-molecules-28-04183" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Duval</surname><given-names>Rapha&#x000eb;l E.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-28-04183"><label>1</label>Translational Biomedical Sciences Program, Ohio University, Athens, OH 45701, USA; <email>yy506416@ohio.edu</email> (Y.Y.); <email>marchan@ohio.edu</email> (M.R.M.-R.)</aff><aff id="af2-molecules-28-04183"><label>2</label>Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA; <email>mk209219@ohio.edu</email></aff><aff id="af3-molecules-28-04183"><label>3</label>Honors Tutorial College, Ohio University, Athens, OH 45701, USA</aff><aff id="af4-molecules-28-04183"><label>4</label>Department of Biological Sciences, Ohio University, Athens, OH 45701, USA</aff><aff id="af5-molecules-28-04183"><label>5</label>Center for Research on Health in Latinamerica (CISeAL)-Biological Science Department, Pontificia Universidad Cat&#x000f3;lica del Ecuador (PUCE), Quito 170143, Ecuador</aff><aff id="af6-molecules-28-04183"><label>6</label>Department of Chemistry and Biochemistry, Ohio University, Athens, OH 45701, USA</aff><author-notes><corresp id="c1-molecules-28-04183"><label>*</label>Correspondence: <email>hany@ohio.edu</email>; Tel.: +1-740-566-0007</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2023</year></pub-date><volume>28</volume><issue>10</issue><elocation-id>4183</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2023</year></date><date date-type="rev-recd"><day>15</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Constantly evolving drug-resistant &#x0201c;superbugs&#x0201d; have caused an urgent demand for novel antimicrobial agents. Natural products and their analogs have been a prolific source of antimicrobial agents, even though a high rediscovery rate and less targeted research has made the field challenging in the pre-genomic era. With recent advancements in technology, natural product research is gaining new life. Genome mining has allowed for more targeted excavation of biosynthetic potential from natural sources that was previously overlooked. Researchers use bioinformatic algorithms to rapidly identify and predict antimicrobial candidates by studying the genome before even entering the lab. In addition, synthetic biology and advanced analytical instruments enable the accelerated identification of novel antibiotics with distinct structures. Here, we reviewed the literature for noteworthy examples of novel antimicrobial agents discovered through various methodologies, highlighting the candidates with potent effectiveness against antimicrobial-resistant pathogens. </p></abstract><kwd-group><kwd>antimicrobial resistance</kwd><kwd>genome mining</kwd><kwd>natural products</kwd><kwd>antibiotics</kwd><kwd>biosynthesis gene clusters</kwd></kwd-group><funding-group><award-group><funding-source>Konneker Research Fund</funding-source></award-group><award-group><funding-source>Edison Biotechnology Institute</funding-source></award-group><award-group><funding-source>Ohio University</funding-source></award-group><award-group><funding-source>Kopchick Research Fellowship Award</funding-source></award-group><funding-statement>This work is supported by the Konneker Research Fund, Edison Biotechnology Institute, the Translational Biomedical Sciences program at Ohio University, and John J. Kopchick Research Fellowship Award to Yuehan Yang. </funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-28-04183"><title>1. Introduction</title><p>Antimicrobial-resistant pathogens have always been a serious threat associated with high morbidity and mortality. Multidrug-resistant &#x0201c;superbugs&#x0201d; and emerging new pathogens seem to have brought back the &#x0201c;pre-antibiotic era&#x0201d;, leaving healthcare providers with limited clinical treatment options [<xref rid="B1-molecules-28-04183" ref-type="bibr">1</xref>]. Since the first discovery and application of antibiotics in the middle of the last century, resistance has been observed, which may predate antibiotics by millions of years [<xref rid="B2-molecules-28-04183" ref-type="bibr">2</xref>]. Microbes use many resistance mechanisms to protect themselves from antibiotics&#x02019; cytotoxic or cytostatic effects. Resistant microbes are naturally selected for exposure to common antibiotics that inhibit or kill sensitive counterparts. Moreover, due to lack of competition, the resistant strains can easily grow, spread, and become &#x0201c;superbugs&#x0201d;, such as methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) and multidrug-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic>, which often respond poorly to existing medications. </p><p>The Centers for Disease Control and Prevention report over 2.8 million antimicrobial-resistant infections in the United States each year, accounting for more than 35,000 deaths [<xref rid="B3-molecules-28-04183" ref-type="bibr">3</xref>]. In addition, the threat of antimicrobial-resistant infections has gotten worse. The COVID-19 pandemic resulted in increased antibiotic use, increased hospitalization-related infections, and decreased progress against antibiotic-resistant infections in the U.S. [<xref rid="B4-molecules-28-04183" ref-type="bibr">4</xref>]. Meanwhile, sharp declines in the introduction of novel antibiotics and an associated decline in pharmaceutical industry investment have exacerbated the resistance threat [<xref rid="B2-molecules-28-04183" ref-type="bibr">2</xref>]. Antibiotics with novel structures and new modes of action have been and will always be urgently needed. </p><p>Natural products (NPs) and their derivatives have historically served as a prolific source of therapeutics, specifically antibiotics, throughout the history of medicine. After the golden age of natural product discovery from the 1940s to 1950s, the pharmaceutical industry mostly favored structural modifications and semi-synthetic analogs of existing compounds to generate new antibiotics [<xref rid="B5-molecules-28-04183" ref-type="bibr">5</xref>]. <xref rid="molecules-28-04183-f001" ref-type="fig">Figure 1</xref> illustrates the structural evolution of three generations of polyketide antibiotics based on erythromycin. Erythromycin (<bold>1</bold>) is a type I polyketide antibiotic produced by <italic toggle="yes">Saccharopolyspora erythraea</italic> with a 14-membered macrolactone ring and two glucose-derived deoxysugar moieties. The semisynthetic derivatives, clarithromycin (<bold>2</bold>) (methylation at the 6-hydroxy group and 14-membered lactone ring same with erythromycin) and azithromycin (<bold>3</bold>) (15-membered ring and 9-carbonyl group replaced with a methyl-substituted nitrogen), show an enhanced spectrum of activity and are active against erythromycin-resistant <italic toggle="yes">Streptococcus pneumoniae</italic>. However, such efforts far from meet the challenges of antimicrobial-resistant and emerging pathogens. Fortunately, new NP discovery efforts continue to flourish with promising results. In particular, recent genomic and bioinformatic-guided approaches have profoundly accelerated the process of novel antimicrobial agent discovery and overcome the pitfall of a high rediscovery rate through the traditional approaches [<xref rid="B6-molecules-28-04183" ref-type="bibr">6</xref>,<xref rid="B7-molecules-28-04183" ref-type="bibr">7</xref>]. With the advances in genomics uncovering silent gene clusters, researchers can activate silent gene clusters and obtain the encoded compounds through various techniques. Here, we reviewed the literature from 2002 to 2022 and discussed new compounds against antimicrobial-resistant pathogens discovered by genome mining of natural sources and beyond. In addition, this review examined the antimicrobial mode of action and mechanism of resistance to commonly used therapeutics.</p></sec><sec id="sec2-molecules-28-04183"><title>2. Genome Mining for Key Enzymes in Biosynthesis Gene Clusters</title><p>Genome mining is a bioinformatic approach used to discover and analyze the biosynthesis genetic potential of natural products in the genome of organisms, such as plants, bacteria, and fungi. The most common genome mining approach is to apply computational algorithms to analyze biosynthetic gene clusters (BGCs), targeting known enzymatic or gene functions, particularly core biosynthesis enzymes and specific structural unit biosynthesis enzymes. The underlining rationale is that natural products are assembled, tailored, and regulated by strikingly conservative BGCs. These BGCs are responsible for composing production lines in natural organisms such as microbes, fungi, and plants [<xref rid="B8-molecules-28-04183" ref-type="bibr">8</xref>]. </p><p>A typical roadmap of genome mining is elucidated in <xref rid="molecules-28-04183-sch001" ref-type="fig">Scheme 1</xref>, which represents the discovery of a novel antibiotic through the excavation of bacterial genomes. The natural compound producers were collected from various sources and genomes were sequenced and analyzed for BGCs. Then, researchers used computational algorithms to predict the enzymatic modules and post-assembly tailoring enzymes, as exemplified by the discovery of the novel antibiotic ECO-0501 [<xref rid="B9-molecules-28-04183" ref-type="bibr">9</xref>]. The producer strain <italic toggle="yes">Amycolatopsis orientalis</italic> ATCC 43491 was known to be a vancomycin-producing strain. A whole genome analysis indicated it harbors over ten BGCs besides vancomycin. Next, researchers expressed and characterized one of the clusters. A fermentation and chromatography-based separation yielded purified compound(s). Subsequently, structure elucidation through mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR) revealed the structure of a new glycosidic polyketide ECO-0501(<bold>4</bold>). ECO-0501 exhibits strong antibacterial activity against MRSA (MIC: 4.8 &#x003bc;M) and vancomycin-resistant <italic toggle="yes">Enterococci</italic> (VRE) (MIC: 10 &#x003bc;M) [<xref rid="B9-molecules-28-04183" ref-type="bibr">9</xref>]. </p><p>BGCs encode enzymes that are responsible for the synthesis of several classes of compounds, including polyketides, nonribosomal peptides, ribosomally synthesized and post-translationally modified peptides, phenazines, and terpenes, among others. Next, we discuss the discovery of novel antimicrobial compounds from the aforementioned classes through various genome-mining approaches. </p><sec id="sec2dot1-molecules-28-04183"><title>2.1. Polyketides</title><p>Polyketides are biosynthesized by polyketide synthases (PKSs) using acyl-CoA as a precursor. Generally, bacterial type I PKSs have multiple enzymatic modules, each module only adds one unit of acyl-CoA to elongate the polyketide chain, and subsequent catalysis often leads to the formation of the macrocycle (e.g., erythromycin (<bold>1</bold>) in <xref rid="molecules-28-04183-f002" ref-type="fig">Figure 2</xref>). In contrast, bacterial type II PKSs act iteratively, with one enzymatic module being used repeatedly to grow the polyketide chain. Subsequent steps often lead to the formation of a polycyclic aromatic skeleton (e.g., tetracenomycin (<bold>5</bold>) in <xref rid="molecules-28-04183-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B10-molecules-28-04183" ref-type="bibr">10</xref>]. The understanding of the biosynthetic rationale behind polyketides has come a long way; using this extensive information, guidelines for predicting cryptic polyketide structures and activity from genome sequences have been developed [<xref rid="B11-molecules-28-04183" ref-type="bibr">11</xref>]. </p><p>Besides the example of type I polyketide ECO-0501 we discussed above, additional compounds were discovered through a similar approach. Anthracimycin (<bold>6</bold>), a promising type I polyketide antibiotic with a unique structure, produced by marine-derived <italic toggle="yes">Streptomyces</italic> sp. CNH365, has shown potent activity against anthrax-causing Bacillus anthracis UM23C1&#x02013;1 (MIC: 0.079 &#x003bc;M) and various antimicrobial-resistance pathogens, such as MRSA (MIC &#x02265; 0.63 &#x003bc;M) and vancomycin-resistant <italic toggle="yes">S. aureus</italic> (MIC &#x02265; 0.63 &#x003bc;M) [<xref rid="B12-molecules-28-04183" ref-type="bibr">12</xref>]. Anthracimycin has been shown to protect animals from MRSA-induced mortality in a murine model of infection, and macromolecular synthesis studies suggest that it may inhibit RNA and/or DNA synthesis of bacteria [<xref rid="B13-molecules-28-04183" ref-type="bibr">13</xref>]. Similarly, the PKS gene cluster in the genome of the myxobacterium <italic toggle="yes">Pyxidicoccus fallax</italic> was investigated, and genes encoding pentapeptide repeat proteins, known to confer resistance to topoisomerase inhibitors, were found in the cluster. Its activation in the natural host and heterologous expression allowed the discovery of pyxidicyclines (e.g., pyxidicyclin A (<bold>7</bold>)) and precursor anthraquinones [<xref rid="B14-molecules-28-04183" ref-type="bibr">14</xref>]. </p><p>The heterologous expression approach is often combined with the resistance gene screening approach. Using these two combined approaches, a PKS&#x02013;NRPS hybrid gene cluster led to the discovery of a series of thiotetronic acid natural products, including the previously known fatty acid synthase inhibitor thiolactomycin (<bold>8</bold>), which has moderate activity against MRSA, <italic toggle="yes">Mycobacterium tuberculosis</italic>, <italic toggle="yes">Plasmodium falciparum</italic>, and <italic toggle="yes">Francisella tularensis</italic> [<xref rid="B15-molecules-28-04183" ref-type="bibr">15</xref>]. In a subsequent study, the researchers synthesized structural analogs of thiolactomycin which showed enhanced activity (e.g., TLM 9 (<bold>9</bold>) showed a 75-fold improvement against MRSA) (Bommineni, 2016). A polyketide with a unique tetracyclic skeleton, isoindolinomycin (<bold>10</bold>), has a BGC which is mutated in the wild-type <italic toggle="yes">Streptomyces</italic> sp. SoC090715LN-16. Through screening of rifampicin-resistant mutants and activation of the biosynthetic gene cluster, isoindolinomycin was discovered and characterized [<xref rid="B16-molecules-28-04183" ref-type="bibr">16</xref>]. Tetracyclic-type antibiotics, which inhibit bacterial growth by specifically binding to bacterial ribosomal subunits, currently face efflux pump-type resistance due to overuse [<xref rid="B17-molecules-28-04183" ref-type="bibr">17</xref>]. Isoindolinomycin may offer new target binding sites and overcome the current antimicrobial resistance issue.</p><p>Other than examining the whole PKS clusters, another common methodology is to screen for key biosynthesize units. The synthase genes for 3-amino-5-hydroxybenzoic acid (AHBA), the starter unit in ansamycin-type antibiotics, were screened in a pool of actinobacteria [<xref rid="B18-molecules-28-04183" ref-type="bibr">18</xref>]. The genome of <italic toggle="yes">Streptomyces</italic> sp. LZ35, an AHBA synthase-positive strain, was further analyzed for novel BGCs. Multiple attempts were then made to successfully activate the silent neoansamycin BGC through transcriptional regulation factors, leading to the discovery of neoansamycins (<bold>11</bold>, <bold>12</bold>) [<xref rid="B19-molecules-28-04183" ref-type="bibr">19</xref>,<xref rid="B20-molecules-28-04183" ref-type="bibr">20</xref>]. </p><p>Sometimes silent BGCs can be activated through adjustment of the microbial culture conditions. Keyicin (<bold>13</bold>), a poly-nitroglycosylated anthracycline antibiotic, was discovered by co-culturing two marine bacteria from the otherwise silent PKS gene cluster in the producing strain <italic toggle="yes">Micromonospora</italic> sp. In addition to its possible interspecies crosstalk function, keyicin exhibits selective antimicrobial activity against Gram-positive bacteria including <italic toggle="yes">Rhodococcus</italic> sp. and <italic toggle="yes">Mycobacterium</italic> sp. and it does not cause nucleic acid damage [<xref rid="B21-molecules-28-04183" ref-type="bibr">21</xref>]. </p><p>Moreover, genomics leveraging analytical techniques (e.g., LC-MS, HPLC, NMR, CryoEM, etc.) [<xref rid="B22-molecules-28-04183" ref-type="bibr">22</xref>,<xref rid="B23-molecules-28-04183" ref-type="bibr">23</xref>,<xref rid="B24-molecules-28-04183" ref-type="bibr">24</xref>,<xref rid="B25-molecules-28-04183" ref-type="bibr">25</xref>,<xref rid="B26-molecules-28-04183" ref-type="bibr">26</xref>] has been used to profile the metabolic phenotypes of microbes for prospecting antibiotics. A discovery platform was built that applies genomics, metabolomics, and antimicrobial activity screening of LC-MS-based metabolomic arrays from 174 marine animal isolated bacteria [<xref rid="B27-molecules-28-04183" ref-type="bibr">27</xref>]. <italic toggle="yes">Micromonospora</italic> sp. WMMC-415&#x02019;s hidden chemical diversity was highlighted and prioritized by its potent activity against <italic toggle="yes">Candida albicans</italic> and led to the discovery of turbinmicin (<bold>14</bold>), a broad-spectrum antifungal drug candidate that targets multidrug-resistant fungi with a high safety profile and a highly selective mechanism of action [<xref rid="B27-molecules-28-04183" ref-type="bibr">27</xref>]. </p><p>Genome mining of BGCs is often combined with activity-guided separation. Clostrubin (<bold>15</bold>), a highly unsaturated aromatic polyketide from an obligate anaerobe <italic toggle="yes">Clostridium beijerinckii</italic>, demonstrated pronounced activity against various pathogenic Gram-positive bacteria, including MRSA (MIC: 0.12 &#x000b5;M), VRE (MIC: 0.97 &#x000b5;M), and mycobacteria (MIC: 0.48 &#x003bc;M), and moderate antiproliferative and cytotoxic effects [<xref rid="B28-molecules-28-04183" ref-type="bibr">28</xref>]. In another study, clostrubin and its analog (<bold>16</bold>) were found to be produced by <italic toggle="yes">Clostridium puniceum</italic> functioning as antibiotics against other plant pathogens, giving the anaerobic bacteria an advantage to compete in an oxygen-rich plant environment [<xref rid="B29-molecules-28-04183" ref-type="bibr">29</xref>]. Clostrubins are an exemplary case of mining the genomic biosynthesis potential in combination with traditional culture condition screening and/or molecular biology tools, leading to the rapid discovery of polyketide antibiotics. </p></sec><sec id="sec2dot2-molecules-28-04183"><title>2.2. Nonribosomal Peptides</title><p>Distinguished from peptides and proteins synthesized from the ribosomal pathway, nonribosomal peptides are assembled by modular machinery consisting of large, selective multifunctional enzymes called nonribosomal peptide synthetases (NRPS). The products of these machineries are many successfully marketed drugs (e.g., penicillin (<bold>18</bold>), vancomycin (<bold>19</bold>), and daptomycin (<bold>20</bold>) shown in <xref rid="molecules-28-04183-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B30-molecules-28-04183" ref-type="bibr">30</xref>]. Over the last few decades, the complicated production process of nonribosomal peptides has been the subject of biochemical and structural biology investigations, offering new compounds with pharmaceutical value. </p><p>Straightforwardly, conserved genes of BGCs can be screened to mine new nonribosomal peptides with pharmaceutical value. Twenty-seven marine actinomycete isolates were subjects for NRPS and PKS gene screening, and coupled with a bioactivity assay, this led to the identification of <italic toggle="yes">Nocardiopsis</italic> sp. TFS65-07. Further isolation and examination determined the active compound to be TP-1161 (<bold>21</bold>), a new macrocyclic thiopeptide with three thiazole and two oxazole groups. TP-1161 displayed superior activity against a panel of Gram-positive pathogens including VRE (MIC: 0.84 &#x003bc;M), and the mode of action for thiopeptide is yet to be determined [<xref rid="B31-molecules-28-04183" ref-type="bibr">31</xref>]. Similarly, genome mining of NRPS gene clusters in <italic toggle="yes">Brevibacillus laterosporus</italic> DSM 25 led to the discovery of Brevibacillin 2V (<bold>22</bold>), which has a strong antimicrobial activity against difficult-to-treat antimicrobial-resistant Gram-positive pathogens with low hemolytic activities and cytotoxicities to eukaryotic cells. When combined with marketed antibiotics, Brevibacillin 2V demonstrates a synergistic effect against Gram-negative pathogens and shows a high stability in human plasma, most likely because of the inclusion of D-amino acids and non-canonical amino acids [<xref rid="B32-molecules-28-04183" ref-type="bibr">32</xref>]. Likewise, a cyclic lipopeptide medipeptin A (<bold>23</bold>) was isolated from the microbiome of a tomato plant in the Netherlands. Researchers took a sample from the plant and isolated <italic toggle="yes">Pseudomonas</italic> bacteria, the genomic DNA of which was then analyzed for biosynthetic gene clusters. Medipeptin A was isolated and showed good activity against multiple pathogens. Medipeptin A&#x02019;s antibiotic capabilities come from its binding with lipoteichoic acids and by forming pores in the bacterial membrane [<xref rid="B33-molecules-28-04183" ref-type="bibr">33</xref>]. </p><p>Many nonribosomal peptides encoded by unculturable bacteria genomes can be obtained in the heterologous expression hosts. Malacidins (<bold>24</bold>, <bold>25</bold>), which are calcium-dependent nonribosomal lipopeptides, target the cell wall biosynthesis of multidrug-resistant pathogens. The malacidin gene cluster was captured from desert soil metagenomics using primers targeting calcium-binding motifs. To avoid rediscovery, a phylogeny tree of the calcium-dependent antibiotic gene was generated to guide the selection of a novel malacidin gene cluster. Heterologous expression yielded new antibiotic malacidins, whose activity spectrum against multiple drug-resistant pathogens was evaluated and the mode of action was discussed [<xref rid="B34-molecules-28-04183" ref-type="bibr">34</xref>]. Similarly, taromycin A (<bold>26</bold>) and B (<bold>27</bold>) are nonribosomal lipopeptides whose BGCs highly resemble the daptomycin gene cluster. The 67 kb otherwise silent taromycin BGC was directly cloned and refactored into the model expression host <italic toggle="yes">Streptomyces coelicolor</italic>. Taromycins show moderate activity against multiple daptomycin-resistant strains, demonstrating an alternative option for a new antibiotic [<xref rid="B35-molecules-28-04183" ref-type="bibr">35</xref>,<xref rid="B36-molecules-28-04183" ref-type="bibr">36</xref>]. Although the heterologous expression of NRPS clusters often proceeds with difficulty due to the giant gene cluster size (30&#x02013;100 kb), the success of malacidins and taromycins demonstrated new avenues for antibiotic discovery. </p><p>Another breakthrough method to excavate NPs from unculturable bacteria was to grow them directly in their native environments, such as soil and seawater. Teixobactin (<bold>28</bold>) was discovered using a device that allows source bacteria to grow between semipermeable membranes immersed in the original soil sample, enabling nutrients, and signaling molecules to promote growth. Teixobactin represents a new class of antibiotics with excellent activity against Gram-positive pathogens and a non-detectable resistance [<xref rid="B37-molecules-28-04183" ref-type="bibr">37</xref>]. In addition, new antibiotics may come from previously overlooked sources such as the animal microbiome. Lugdunin (<bold>29</bold>) is a thiazolidine-containing nonribosomal peptide that is produced by the human microbiota <italic toggle="yes">Staphylococcus lugdunensis</italic>. Ludunin displays a broad spectrum of activity against Gram-positive pathogens and prevents <italic toggle="yes">S. aureus</italic> from colonizing. Researchers also observed that <italic toggle="yes">S. lugdunensis</italic> nasal colonization was linked to a notably low <italic toggle="yes">S. aureus</italic> carriage rate, indicating that lugdunin or lugdunin-producing commensal bacteria may prevent staphylococcal infections [<xref rid="B38-molecules-28-04183" ref-type="bibr">38</xref>].</p><p>NP bioinformation-guided and organically synthesized peptides are a new approach to rapidly obtaining antimicrobial agents. Macolacin (<bold>30</bold>), an analog of the nonribosomal peptide antibiotic colistin (<bold>31</bold>), is a synthetic bioinformatic natural product generated by chemical synthesis from the BGC-guided approach. Through an extensive search of bacteria genomes for colistin-like BGCs, a BGC from <italic toggle="yes">Paenibacillus xylanexedens</italic> mac was projected to produce a structurally divergent colistin congener. Subsequential chemical syntheses produced macolacin and its derivatives, which exhibit superior activity over colistin against multidrug-resistant pathogens, including drug-resistant <italic toggle="yes">Acinetobacter baumannii</italic> and colistin-resistant <italic toggle="yes">Neisseria gonorrhoeae</italic> [<xref rid="B39-molecules-28-04183" ref-type="bibr">39</xref>]. A similar chemical synthesis approach was applied to produce humimycins, which are MRSA active antibiotics, from human-associated bacteria NRPS clusters. Two NRPS clusters from the genomes of <italic toggle="yes">Rhodococcus equi</italic> and <italic toggle="yes">Rhodococcus erythropolis</italic> predicted the amino acid sequences of humimycins A (<bold>31</bold>) and B (<bold>32</bold>), respectively [<xref rid="B40-molecules-28-04183" ref-type="bibr">40</xref>]. Using synthetic endeavors, more nonribosomal peptides (Paenimucillins (<bold>34</bold>&#x02013;<bold>36</bold>)) and an antifungal peptide (<bold>37</bold>) were discovered. Paenimucillin C (<bold>36</bold>) inhibits multidrug-resistant <italic toggle="yes">Acinetobacter baumannii</italic> clinical isolates and sterilizes multidrug-resistant <italic toggle="yes">A. baumannii</italic> infection with no indication of a rebound in a murine model [<xref rid="B41-molecules-28-04183" ref-type="bibr">41</xref>,<xref rid="B42-molecules-28-04183" ref-type="bibr">42</xref>]. </p><p>The synthetic bioinformatic NP approach bypasses complicated gene cluster activation in the original host, avoids establishing a heterologous expression system for large gene fragments, skips the time-consuming fermentation extraction and isolation, and alleviates the difficulties of complicated peptide structure elucidation. However, synthetic peptides usually cannot generate the final products of the BGCs, partly due to the accuracy of the computational prediction of versatile and complicated post-assembly tailoring enzymes. Despite the limitations, this approach offers adequate peptide skeletons for a structure&#x02013;activity relationship exploration of the analogs. Among post-assembly tailoring enzymes, cytochrome P450s successfully generated activity-improved nonribosomal peptides. Inspired by the significant antibacterial property enhancement of the dimeric products, Guo et al. searched Streptomyces genomes for tailoring enzyme cytochrome P450s with the function of dimerizing structural similar nonribosomal peptides [<xref rid="B43-molecules-28-04183" ref-type="bibr">43</xref>]. The overexpression of two cytochrome P450s in <italic toggle="yes">Streptomyces alboflavus</italic> sp. 313 led to the generation of dimeric nonribosomal peptide di-alboflavusins. Di-alboflavusin A<sub>1</sub> (<bold>38</bold>) and A<sub>2</sub> (<bold>39</bold>) demonstrate a 10&#x02013;100-fold improvement in antibacterial activity against multiple MRSA strains compared with the counterpart monomers (marked green in <xref rid="molecules-28-04183-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B43-molecules-28-04183" ref-type="bibr">43</xref>]. <xref rid="molecules-28-04183-f003" ref-type="fig">Figure 3</xref> shows the nonribosomal peptides discussed in this section. </p></sec><sec id="sec2dot3-molecules-28-04183"><title>2.3. Ribosomally Synthesized and Post-Translationally Modified Peptides</title><p>Ribosomally synthesized and post-translationally modified peptides (RiPPs) present high complexity and miscellaneous bioactivities for pharmacological applications [<xref rid="B44-molecules-28-04183" ref-type="bibr">44</xref>]. The intricate RiPP molecular structures arise from diverse peptide skeletons and complex post-assembly modifications, generating linear peptides, cyclic peptides, lanthipeptides, lasso peptides, thiopeptides, lipopeptides, glycopeptides, etc., presenting many unique drug candidates for antimicrobial-resistant infections [<xref rid="B45-molecules-28-04183" ref-type="bibr">45</xref>]. </p><p>Many RiPPs are found through simple genome mining for BGCs. Lactocillin (<bold>40</bold>), a thiopeptide antibiotic, is a classic example of a product of massive genome data mining of bacterial BGCs from unconventional biological systems. Lactocillin BGC from a vaginal microbiota genome was pinpointed out of 3118 BGCs from human-associated bacteria genomes. Lactocillin displayed potent activity against vaginal pathogens. Additionally, metatranscriptomic sequencing data show that lactocillin is expressed in the human vagina in vivo, suggesting vaginal microbiota may inhibit pathogenic bacteria and prevent vaginal infections through the expression of lactocillin-type thiopeptides [<xref rid="B46-molecules-28-04183" ref-type="bibr">46</xref>]. </p><p>The novel two-peptide lantibiotic lichenicidin (<bold>41</bold>) was isolated from Bacillus licheniformis D13 and was found using NCBI-BLAST to look through the B. licheniformis genome to detect gene clusters that could produce novel lantibiotics. Lantibiotics are a class of RiPP antibiotics characterized by post-translational addition of the thioether amino acids lanthionine and methyllanthionine [<xref rid="B47-molecules-28-04183" ref-type="bibr">47</xref>]. Lichenicidin has activities against Bacillus megaterium, Bacillus subtilis, <italic toggle="yes">S. aureus</italic>, Micrococcus luteus, and Rhodococcus spp. [<xref rid="B48-molecules-28-04183" ref-type="bibr">48</xref>]. Another RiPP found through genome mining of BGCs is thiomuracin (<bold>42</bold>). Thiomuracin is a thiopeptide found by genome mining of the bacterium <italic toggle="yes">Thermobispora bispora.</italic> The peptide has strong activities against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> USA300 (MIC of 0.18 &#x003bc;M) and vancomycin-resistant <italic toggle="yes">Enterococcus faecium</italic> U503 (MIC of 0.046 &#x003bc;M). The peptide also has an MIC of 1.5 &#x003bc;M against spore-forming Bacillus anthracis str. Sterne. Thiomuracin is post-translationally modified into a cyclic structure that has inhibitory effects on bacterial protein synthesis [<xref rid="B49-molecules-28-04183" ref-type="bibr">49</xref>]. </p><p>Other novel RiPPs were found through targeted genome mining, where an analog or type of gene cluster was searched for. Specialicin (<bold>43</bold>) is a lasso peptide that was found by searching the Streptomyces specialis genome for analogs of known peptides. A BLAST search was run, looking for BGCs that were similar to those of siamycin. Specialicin was then found, isolated, and tested, which revealed an MIC of 3.75 &#x003bc;M against M. luteus [<xref rid="B50-molecules-28-04183" ref-type="bibr">50</xref>]. Another lasso peptide, Lassomycin (<bold>44</bold>), showed promising activities against <italic toggle="yes">Mycobacterium tuberculosis</italic> (0.41&#x02013;1.65 &#x003bc;M), including many resistant strains (0.21&#x02013;1.65 &#x003bc;M). Lassomycin was found in an extract of <italic toggle="yes">Lentzia kentuckyensis</italic>. It is an interesting lasso peptide because its N-terminus tail does not string through its macrolactam ring similar to many other lasso peptides [<xref rid="B51-molecules-28-04183" ref-type="bibr">51</xref>]. </p><p>Promoter engineering and synthetic modular regulatory elements have successfully turned on silent BGCs for new NP production and constructed overproducing strains of known antibiotics [<xref rid="B52-molecules-28-04183" ref-type="bibr">52</xref>]. New bottromycin derivatives with 5&#x02013;50-fold higher titers of bottromycin A<sub>2</sub> (<bold>45</bold>) were generated by replacing native promoters with randomized constitutive synthetic promoters. The expression of the bottromycin gene cluster is decoupled from intricate native regulatory networks via promoter engineering and heterologous expression. Additionally, this tactic enhanced the production of bottromycins, a class of macrocyclic peptides with antimicrobial activities against multidrug-resistant bacteria [<xref rid="B53-molecules-28-04183" ref-type="bibr">53</xref>,<xref rid="B54-molecules-28-04183" ref-type="bibr">54</xref>]. </p><p>Some RiPPs are heterologously expressed in a different host than the gene they are found in, one such compound is citrocin (<bold>46</bold>). Citrocin is an antimicrobial lasso peptide found in both <italic toggle="yes">Citrobacter pasteurii</italic> and <italic toggle="yes">Citrobacter braakii</italic>. It was heterologously expressed in Escherichia coli and then isolated. Its structure was determined, and MIC values were calculated for its antimicrobial activities against a handful of species. Citrocin displayed an MIC ranging from 16&#x02013;100 &#x003bc;M for <italic toggle="yes">E. coli</italic> species with 16 &#x003bc;M for enterohemorrhagic <italic toggle="yes">E. coli</italic> O157:H7 strain TUV93-0. The compound also displayed an MIC of 1000 &#x003bc;M against <italic toggle="yes">Salmonella enterica</italic> serovar Newport and 125 &#x003bc;M against a clinical isolate of Citrobacter [<xref rid="B52-molecules-28-04183" ref-type="bibr">52</xref>]. An additional compound, venezeulin (<bold>47</bold>), was found by genome mining for lantibiotic synthetases [<xref rid="B55-molecules-28-04183" ref-type="bibr">55</xref>]. Venezeulin, isolated from <italic toggle="yes">Streptomyces venezuelae</italic>, is heterologously produced in <italic toggle="yes">E. coli</italic> BL21 [<xref rid="B56-molecules-28-04183" ref-type="bibr">56</xref>]. </p><p>Similar to synthetic bioinformatic nonribosomal peptides, RiPPs can be synthetically produced. TL19 (<bold>48</bold>) is an antibiotic peptide (MIC of 0.9 to 15 &#x003bc;M against E. faecium) made by synthetically combining the N-terminus portion of nisin and the C-terminus portion of haloduracin &#x003b1; (HalA1 is one of the two peptides that make up the lanthipeptide haloduracin) [<xref rid="B56-molecules-28-04183" ref-type="bibr">56</xref>]. Nisin, an FDA-approved safe peptide food preservative with potential for clinical use, is a well-studied 34-residue lantibiotic that is produced by <italic toggle="yes">Lactococcus lactis</italic>, where its synthesis is regulated by a two-component regulatory system. Haloduracin is a two-peptide antibiotic. Both HalA1 and Nisin contain a lipid II binding site [<xref rid="B57-molecules-28-04183" ref-type="bibr">57</xref>]. The aforementioned representative RiPP antibiotics are shown in <xref rid="molecules-28-04183-f004" ref-type="fig">Figure 4</xref>. </p></sec><sec id="sec2dot4-molecules-28-04183"><title>2.4. Phenazines</title><p>The fundamental structure of phenazines is composed of redox-active nitrogen tricyclic aromatic rings; however, they differ in the modification groups. Many phenazines have broad spectrum antimicrobial properties, making them prospective antibiotics [<xref rid="B58-molecules-28-04183" ref-type="bibr">58</xref>,<xref rid="B59-molecules-28-04183" ref-type="bibr">59</xref>,<xref rid="B60-molecules-28-04183" ref-type="bibr">60</xref>]. The biosynthesis of the phenazine core structure (marked pink in <xref rid="molecules-28-04183-f005" ref-type="fig">Figure 5</xref>), which diverges from the shikimic acid pathway, has been well studied. Bacterial producers have a conserved set of phenazine biosynthesis genes (PHZ) that encode enzymes that convert chorismic acid into complex phenazine precursors phenazine-1-carboxylic acid (PCA) (<bold>49</bold>) or phenazine-1,6-dicarboxylic acid (PDC) (<bold>50</bold>) [<xref rid="B61-molecules-28-04183" ref-type="bibr">61</xref>]. Similar tactics have been employed to unearth new phenazines to those used for other classes of antibiotics discussed previously. </p><p>Phenazine BGC screening and bioactivity-guided isolation are two commonly combined approaches to excavate new phenazine antibiotics. A bioinformatics analysis of Kitasatospora sp. HKI 714 genome revealed phenazine BGC and the subsequent bioactivity-guided isolation revealed new terpenoid-substituted phenazines endophenazine A1 (<bold>51</bold>), F (<bold>52</bold>), and G (<bold>53</bold>). Heine et al. analyzed the biological effects of the new endophenazines, mostly concentrating on their antibacterial properties against various mycobacteria and MRSA [<xref rid="B62-molecules-28-04183" ref-type="bibr">62</xref>]. Our group applied the bioinformatic tool antiSMASH 6.0 [<xref rid="B63-molecules-28-04183" ref-type="bibr">63</xref>] to analyze the genome of <italic toggle="yes">Amycolatopsis nigrescens</italic> DSM 44992, revealing one phenazine BGC as well as thirty other BGCs. An antimicrobial-activity-guided isolation revealed a novel phenazine compound YYH001 (<bold>54</bold>), whose absolute structure was determined by crystallography. However, additional bioactivity assays did not find appreciable antibiotic properties of the purified YYH001. We speculated that the superior activity against bacterial and fungal pathogens was brought by other BGC products of the crude extract. In fact, we successfully identified a family of novel polyketide antibiotics from a PKS gene cluster in <italic toggle="yes">Amycolatopsis nigrescens</italic>. Besides the assessment of BGCs, researchers often use universal primers of conserved genes to find the microbes&#x02019; genetic potential for antibiotic production. This approach is still suitable for cost-effective and time-efficient screening of large numbers of microorganisms. We used universal gene phzE primers to evaluate a pool of actinobacteria that our group isolated from unusual biosamples. The positive strain <italic toggle="yes">Streptomyces</italic> sp. B23 isolated from a soil sample was selected for further investigation. A bioactivity-guided separation led to the discovery of a novel antibiotic kephenamycine (<bold>55</bold>), along with several known phenazines (e.g., saphenamycin (<bold>56</bold>)). </p><p>The diverse bioactivity of phenazines arises from a variety of modifications to the core. Shi et al. reported that the entomopathogenic bacterium <italic toggle="yes">Xenorhabdus szentirmaii</italic> underwent multiple modifications of the phenazine core through two different BGCs, generating derivatives with phenazine&#x02013;polyketide hybrid scaffolds (e.g., phenaszenketide A&#x02013;C (<bold>57</bold>&#x02013;<bold>59</bold>)) and phenazine&#x02013;peptide hybrid scaffolds (e.g., pelagiomicin B (<bold>60</bold>) and phenaszentine C (<bold>61</bold>)). The two BGC pathways were connected via a common aldehyde intermediate altered by several enzymatic and non-enzymatic reactions. The evaluation of the antibiotic activity of the generated phenazine derivatives points to a highly efficient method for converting the phenazines with specialized activity against Gram-positive bacteria into broad spectrum antibiotics [<xref rid="B64-molecules-28-04183" ref-type="bibr">64</xref>]. However, the antibiotic activity of phenazines against pathogens was evaluated via diameters of inhibition zones in disc diffusion assays and lack of replications; MICs against antimicrobial-resistant pathogens need to be conducted to comprehensively assess their antibiotic properties. Other research discussed the antibacterial mode of action of a structurally similar phenazine&#x02013;peptide <sub>D</sub>-alanylgriseoluteic acid (<bold>62</bold>), which induced the SOS response through the endogenous redox activity of the compound [<xref rid="B65-molecules-28-04183" ref-type="bibr">65</xref>]. Other types of phenazine antibiotic modification seen in nature include glycosylation (e.g., endophenazine B (<bold>63</bold>) and C (<bold>64</bold>)) [<xref rid="B66-molecules-28-04183" ref-type="bibr">66</xref>], dimerization (e.g., esmeraldin B (<bold>65</bold>) and diastaphenazine (<bold>66</bold>), two cores marked pink in <xref rid="molecules-28-04183-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B67-molecules-28-04183" ref-type="bibr">67</xref>,<xref rid="B68-molecules-28-04183" ref-type="bibr">68</xref>], and N-oxidation (e.g., myxin (<bold>67</bold>) and iodinin (<bold>68</bold>)) [<xref rid="B69-molecules-28-04183" ref-type="bibr">69</xref>], among others. </p><p>Activation of silent gene clusters poses one of the major challenges of genome mining for new antibiotics. Low doses of antibiotics may act as signaling molecules that can activate or modulate BGCs. Streptophenazines A&#x02013;H (<bold>69</bold>&#x02013;<bold>76</bold>), a family of new phenazines, were found in a marine Streptomyces isolate. The production pattern of streptophenazines depends on the different antibiotics added to the culture conditions which act as signaling molecules. Specifically, tetracycline induces streptophenazine F and G production and increases the yield of streptophenazine A&#x02013;D, whereas bacitracin induces streptophenazine H production. The streptophenazines showed moderate activity against Bacillus subtilis as well as Staphylococcus lentus [<xref rid="B70-molecules-28-04183" ref-type="bibr">70</xref>]. Heterologous expression and promoter engineering may also activate silent phenazine BGCs. A remarkable chemical diversity of streptophenazines was produced by heterologous expression and refactoring promoters of a PHZ/PKS/NRPS hybrid gene cluster from <italic toggle="yes">Streptomyces</italic> sp. CNB-09. Among the 112 isolated compounds, a streptophenazine analog containing an unprecedented N-formylglycine moiety (marked in blue in <xref rid="molecules-28-04183-f005" ref-type="fig">Figure 5</xref>), streptophenazine Q (<bold>77</bold>), demonstrated an effective antibiotic activity against MRSA and disease-causing group A <italic toggle="yes">Streptococcus</italic>. However, the heterologous expression of phenazine BGCs can be challenging due to the antibiotic effect of the products on the heterologous host without a proper resistance mechanism [<xref rid="B71-molecules-28-04183" ref-type="bibr">71</xref>]. The endophenazine BGC in the original host (Streptomyces anulatus) produces a much higher yield of antibiotic endophenazine A (<bold>78</bold>) than the heterologous host Streptomyces coelicolor M512. The authors found that the heterologous host strains accumulated a glutamine adduct (marked in blue in <xref rid="molecules-28-04183-f005" ref-type="fig">Figure 5</xref>) endophenazine E (<bold>79</bold>), which does not have antibiotic activity, and they speculated that glutamination could be a defense mechanism of the host [<xref rid="B72-molecules-28-04183" ref-type="bibr">72</xref>,<xref rid="B73-molecules-28-04183" ref-type="bibr">73</xref>]. </p><p>Furthermore, NP-inspired organic synthesized phenazines exhibit extraordinary pharmaceutical value against antimicrobial-resistant pathogens and eradicate persistent pathogen biofilms. Clofazimine (<bold>80</bold>) has been applied to treat multidrug-resistant Mycobacteria tuberculosis, may compete with an essential component in the mycobacterial electron transfer chain, and releases reactive oxygen species [<xref rid="B74-molecules-28-04183" ref-type="bibr">74</xref>]. Clofazimine derivatives (<bold>81</bold> and <bold>82</bold>), which displayed a remarkable potency improvement in vitro and reduced lipophilic-associated side effects, were further examined for pharmacokinetic profiles in vivo [<xref rid="B75-molecules-28-04183" ref-type="bibr">75</xref>,<xref rid="B76-molecules-28-04183" ref-type="bibr">76</xref>,<xref rid="B77-molecules-28-04183" ref-type="bibr">77</xref>]. Coelho et al. examined the in vitro activity of several phenazine derivatives against rifampicin-resistant <italic toggle="yes">M. tuberculosis</italic> and pan-susceptible <italic toggle="yes">M. tuberculosis</italic> H37Rv and found that the allyl-pyran-group-containing phenazine (<bold>83</bold>) showed an MIC of 2.2 &#x003bc;M and the bromo-pyran-group-containing phenazine (<bold>84</bold>) showed an MIC of 16 &#x003bc;M [<xref rid="B78-molecules-28-04183" ref-type="bibr">78</xref>]. More excitingly, marine brominated phenazine (<bold>85</bold>) inspired the synthesis of a series of halogenated phenazines (e.g., <bold>86</bold>&#x02013;<bold>87</bold>) whose structure&#x02013;activity relationships were thoroughly investigated by Prof. Huigens and colleagues. Potent halogenated phenazine analogs successfully eradicated biofilms formed by persistent pathogens through rapid induction of iron starvation with minimal mammalian cytotoxicity and hemolysis. These findings informed and encouraged the design of rational prodrugs for pharmacological translation [<xref rid="B79-molecules-28-04183" ref-type="bibr">79</xref>,<xref rid="B80-molecules-28-04183" ref-type="bibr">80</xref>,<xref rid="B81-molecules-28-04183" ref-type="bibr">81</xref>,<xref rid="B82-molecules-28-04183" ref-type="bibr">82</xref>]. The structures of the aforementioned representative phenazines are shown in <xref rid="molecules-28-04183-f005" ref-type="fig">Figure 5</xref>. </p></sec><sec id="sec2dot5-molecules-28-04183"><title>2.5. Terpenes/Terpenoids</title><p>Terpenes are often thought to be the largest class of natural products. They often come from plants but are also common in fungi and bacteria. Terpenes are made of repeating isoprene units and typically have carbons in multiples of five because of the five-carbon nature of isoprenes [<xref rid="B83-molecules-28-04183" ref-type="bibr">83</xref>]. Specifically, terpenoids are compounds made of isoprene units that may contain functional groups such as oxygen, while terpenes are hydrocarbons composed only of hydrogen and carbon atoms, but these terms are often used interchangeably in the literature [<xref rid="B84-molecules-28-04183" ref-type="bibr">84</xref>]. </p><p>A BGC analysis can also indicate the genetic potential of producing terpene-type antimicrobials. Researchers sequenced the genome of actinobacteria <italic toggle="yes">Streptomyces</italic> spp. NRRL S-4 and searched for pentalenolactone analogs using the antiSMASH platform. The results revealed six terpene BCGs. Two were determined to produce two sesquiterpenoids 1-deoxy-8&#x003b1;-hydroxypentalenic acid (<bold>88</bold>) and 1-deoxy-9&#x003b2;-hydroxy-11-oxopentalenic acid (<bold>89</bold>). These two compounds had MICs of 64 and 61 &#x003bc;M, respectively, against <italic toggle="yes">S. aureus</italic> ATCC 25923 and 128 and 61 &#x003bc;M against <italic toggle="yes">E. coli</italic> ATCC 25922, respectively [<xref rid="B85-molecules-28-04183" ref-type="bibr">85</xref>]. Another terpenoid found through genome mining is benditerpenoic acid (<bold>90</bold>). The BGC of benditerpenoic acid, a novel bicyclic diterpenoid, was found in the genome of <italic toggle="yes">Streptomyces</italic> sp. CL12-4. The compound was then heterologously expressed in <italic toggle="yes">E. coli</italic>, isolated, and tested to find its MIC against <italic toggle="yes">E. faecium</italic> (401 &#x003bc;M), <italic toggle="yes">S. aureus</italic> (200 &#x003bc;M), MRSA (200 &#x003bc;M), multidrug-resistant <italic toggle="yes">S. aureus</italic> (401 &#x003bc;M), and <italic toggle="yes">B. subtilis</italic> (100 &#x003bc;M) [<xref rid="B86-molecules-28-04183" ref-type="bibr">86</xref>].</p><p>More often, terpenoids are found through the traditional approach of bioactivity screening of extracts or broths. <italic toggle="yes">Sarcophyton trocheliophorum,</italic> a species of soft coral found in the Red Sea, has been found to produce five terpenoid compounds. Two of these compounds are novel and pyrane-based and were exemplified by sarcotrocheliol (<bold>91</bold>). Sarcotrocheliol showed substantial antibiotic activity with MICs of 1.53 &#x003bc;M against <italic toggle="yes">S. aureus</italic> and 3.06 &#x003bc;M against MRSA. Cembrene-C (<bold>92</bold>) was also isolated from this coral and had impressive antifungal activities, with an MIC of 0.68 &#x003bc;M against <italic toggle="yes">Candida albicans</italic> and <italic toggle="yes">Aspergillus flavus</italic> [<xref rid="B87-molecules-28-04183" ref-type="bibr">87</xref>]. A marine sponge of the genus <italic toggle="yes">Hippospongia</italic> found in Fiji produced the sesquiterpenoid quinone epi-ilimaquinone (<bold>93</bold>). This natural product had antibiotic activities of 182 &#x003bc;M against MRSA, 91 &#x003bc;M against <italic toggle="yes">S. aureus</italic>, 45 &#x003bc;M against VRE, and 364 &#x003bc;M against amphotericin-resistant <italic toggle="yes">Candida albicans</italic> [<xref rid="B88-molecules-28-04183" ref-type="bibr">88</xref>]. </p><p>Among many terpenes and terpenoids, one class of compounds has very distinct chemical properties. The diterpene sordarin (<bold>94</bold>), a glycoside antibiotic with a tetracyclic diterpene core, was first discovered in the 1970s and isolated from <italic toggle="yes">Sordaria araneosa</italic>. Sordarin has been studied increasingly since its discovery to allow for the discovery of more, similar antimicrobial compounds [<xref rid="B89-molecules-28-04183" ref-type="bibr">89</xref>,<xref rid="B90-molecules-28-04183" ref-type="bibr">90</xref>]. The antifungal agent targets elongation factor II and halts protein synthesis. Sordarin is the subject of many studies now, with the aim of finding new analogs through genome mining and synthesis. Kudo et al. studied the genome sequence of <italic toggle="yes">Sodaria araneosa</italic> Cain ATCC 36386 to reveal the sordarin biosynthesis pathway. Understanding the biosynthesis of sordarin allows for the targeted synthesis of analogs. FR290581 (<bold>95</bold>), a sordarin analog, was synthesized by modification of sordaricin. It has an enhanced activity (MIC of 0.781&#x02013;1.56 &#x003bc;M) against <italic toggle="yes">Candida</italic> species [<xref rid="B90-molecules-28-04183" ref-type="bibr">90</xref>]. Another analog, GR193663 (<bold>96</bold>), was synthesized by fusing the sugar moiety, creating a new innovative structure that had increased antifungal activities. The new compound GR193663 showed superior activity (MICs at the nanomolar level) against <italic toggle="yes">Candida</italic> species [<xref rid="B91-molecules-28-04183" ref-type="bibr">91</xref>]. The structures of the aforementioned terepenes/terpenoids are shown in <xref rid="molecules-28-04183-f006" ref-type="fig">Figure 6</xref>. <xref rid="molecules-28-04183-t001" ref-type="table">Table 1</xref> summarizes the compounds with activity against antimicrobial-resistant pathogens discussed in the above five sections. </p></sec></sec><sec id="sec3-molecules-28-04183"><title>3. Mechanisms of Resistance and Promising Drug Leads</title><p>The discovery of novel compounds through various technologies offers great promise for combating infectious diseases. However, it is equally important to understand the mechanisms of resistance that may arise to develop strategies to minimize the emergence of resistant strains and prolong the effectiveness of these compounds. In this context, it is essential to identify compounds that can serve as promising drug leads for the development of new antibiotics and antifungal drugs. Apart from their potency, promising drug leads should also exhibit favorable pharmacological properties such as a high selectivity and minimal toxicity. In this section, we will discuss some of the compounds that meet these criteria. </p><sec id="sec3dot1-molecules-28-04183"><title>3.1. Combating Antimicrobial-Resistant Bacteria</title><p>Resistance mechanisms are emerging and currently exist for all currently available antibiotics [<xref rid="B94-molecules-28-04183" ref-type="bibr">94</xref>]. The common resistance mechanisms are summarized in <xref rid="molecules-28-04183-f007" ref-type="fig">Figure 7</xref>. Among the most prescribed drugs, &#x003b2;-lactam antibiotics are characterized by the four-membered cyclic amide ring (e.g., penicillin in <xref rid="molecules-28-04183-f003" ref-type="fig">Figure 3</xref>). &#x003b2;-lactam antibiotics covalently bind to penicillin-binding proteins, which are enzymes involved in the last stages of peptidoglycan cross-linking in bacteria and inhibit the synthesis of bacterial cell walls [<xref rid="B95-molecules-28-04183" ref-type="bibr">95</xref>]. There are at least two common bacterial resistance mechanisms to &#x003b2;-lactam antibiotics: (1) producing &#x003b2;-lactamase, an enzyme that breaks the &#x003b2;-lactam ring structure and (2) producing altered penicillin-binding proteins with a decreased affinity for most &#x003b2;-lactam antibiotics [<xref rid="B96-molecules-28-04183" ref-type="bibr">96</xref>]. Another common type of antibiotic are macrolides, which contain a macrocyclic lactone. Represented by erythromycin (<bold>1</bold>), macrolides impede the bacterial protein synthesis by binding to the 50S ribosomal subunit. Resistance mechanisms of macrolides include (1) upregulating efflux pump expression levels to remove intracellular macrolides, (2) mutating bacterial ribosome proteins and ribosomal RNA, and (3) reducing the binding affinity of the macrolides by phosphorylating the sugar moiety or hydrolyzing the macrocyclic lactone [<xref rid="B97-molecules-28-04183" ref-type="bibr">97</xref>]. In addition, broad spectrum antibiotic rifampin represents the ansamycin-type of antibiotics. Rifampin is a frontline treatment for tuberculosis, whose bactericidal properties stem from high-affinity binding to and inactivating the bacterial DNA-dependent RNA polymerase [<xref rid="B98-molecules-28-04183" ref-type="bibr">98</xref>]. Goldstein argued that rifampin resistance is caused by a genetic modification in the bacterial RNA polymerase &#x003b2; subunit [<xref rid="B99-molecules-28-04183" ref-type="bibr">99</xref>], whereas Javid et al. concluded that phenotypic resistance to rifampicin is caused by the mistranslation of mycobacterial proteins, suggesting that mistakes in protein translation might affect how bacteria respond to stress [<xref rid="B100-molecules-28-04183" ref-type="bibr">100</xref>]. Resistance to conventional antibiotics has caused polymyxins to be reexamined as viable treatment choices. Polymyxins represented by colistin (30) are considered the last resort for multi-drug-resistant Gram-negative pathogens. Colistin exerts a bactericidal effect by binding to the lipid A moiety of lipopolysaccharide, an important Gram-negative bacteria outer surface component, leading to rupture of the cell membrane [<xref rid="B39-molecules-28-04183" ref-type="bibr">39</xref>]. Even though colistin resistance is infrequent due to its limited usage, several strains of colistin-resistant clinical isolates have recently been found. Other than the common antibiotic resistance mechanisms, researchers have speculated that lipopolysaccharide modification may contribute to colistin resistance [<xref rid="B101-molecules-28-04183" ref-type="bibr">101</xref>]. Additional antibiotic examples and molecular targets are summarized in <xref rid="molecules-28-04183-f008" ref-type="fig">Figure 8</xref>. </p><p>The following four antibiotic candidates possess the superior traits of structural innovation and/or unique modes of action that deserve more attention and resources for advanced research of clinical translation. Macolacin (<bold>30</bold>) is an analog of colistin, the discovery of which by genome mining we briefly discussed previously. It is important to examine the mode of action for macolacin to overcome colistin resistance. Wang et al. postulated the distinct structure of macolacin may improve the ability to interact with the lipid A moiety of lipopolysaccharide for colistin-resistant strains. Teixobactin (<bold>28</bold>) inhibits the synthesis of the bacterial cell wall by binding to a highly conserved motif of lipid II and lipid III, both of which are precursors of the bacteria cell wall components (peptidoglycan and teichoic acid, respectively) [<xref rid="B39-molecules-28-04183" ref-type="bibr">39</xref>]. The most outstanding finding is that researchers did not detect acquired resistance after passaging <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">M. tuberculosis</italic> for 25 days with a sub-MIC level of teixobactin, this finding implies the natural resistance to teixobactin may take years to develop. The above two candidates both belong to the nonribosomal peptide category, whereas the next candidate is a ribosomally synthesized peptide with an interesting loop and tail structure. Lassomycin (<bold>44</bold>) targets ATP-dependent protease and kills <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> with a high specificity while offering no hemolysis and low cytotoxicity towards mammalian cells. Without the clear presence of persistence, lassomycin demonstrated a stronger bactericidal effect against stationary <italic toggle="yes">M</italic>. <italic toggle="yes">tuberculosis</italic> than rifampin [<xref rid="B51-molecules-28-04183" ref-type="bibr">51</xref>]. It appears to have a new antimicrobial mode of action by blocking the protein degradation pathway of mycobacteria. Lastly, halogenated phenazines (<bold>83&#x02013;85</bold>) stand out because of their antibiofilm capacity. Unlike most phenazine compounds&#x02019; redox activity-related bactericidal effects, halogenated phenazines bind to metal (II) cations, leading to rapid downstream iron starvation and biofilm eradication. Halogenated phenazine prodrugs were designed based on structure&#x02013;activity relationships with potent effectiveness (minimal biofilm eradication concentration: 0.59&#x02013;18.8 &#x003bc;M) and low toxicity (HeLa cytotox &#x0003e;100 &#x003bc;M and RBC lysis 2.7% at 200 &#x003bc;M), giving the compounds a wide margin of safety [<xref rid="B82-molecules-28-04183" ref-type="bibr">82</xref>]. </p></sec><sec id="sec3dot2-molecules-28-04183"><title>3.2. Combating Antimicrobial-Resistant Fungi</title><p>Antimicrobial-resistant fungal infections are more concerning due to their high motility and the lack of treatment options. Burgeoning organ transplants and use of medical implants, prolonged hospitalization, and the HIV/AIDS and COVID-19 pandemics have dramatically increased the prevalence of life-threatening invasive fungal infections [<xref rid="B103-molecules-28-04183" ref-type="bibr">103</xref>,<xref rid="B104-molecules-28-04183" ref-type="bibr">104</xref>,<xref rid="B105-molecules-28-04183" ref-type="bibr">105</xref>,<xref rid="B106-molecules-28-04183" ref-type="bibr">106</xref>]. Currently, only three classes of antifungal drugs are approved in the clinical practice guidelines for invasive fungal infections and heavily rely on targeting ergosterol in cell membranes and glucans in cell walls [<xref rid="B107-molecules-28-04183" ref-type="bibr">107</xref>,<xref rid="B108-molecules-28-04183" ref-type="bibr">108</xref>,<xref rid="B109-molecules-28-04183" ref-type="bibr">109</xref>,<xref rid="B110-molecules-28-04183" ref-type="bibr">110</xref>]. The over-reliance on limited molecular targets has led to the rapid emergence of antifungal drug resistance. </p><p>The molecular targets of current marketed antifungal drugs and promising new drug leads are elucidated in <xref rid="molecules-28-04183-f009" ref-type="fig">Figure 9</xref>. Frontline treatments (azoles), exemplified by itraconazole, are synthetic antibiotics that inhibit lanosterol 14-&#x003b1;-demethylase and interrupt the synthesis of ergosterol, resulting in the accumulation of toxic sterol intermediates and membrane stress [<xref rid="B111-molecules-28-04183" ref-type="bibr">111</xref>]. Azole resistance mechanisms are developed by (1) altering 14-&#x003b1;-demethylase to decrease the binding affinity, (2) overexpressing efflux pump ABC transporters, and (3) altering sterol biosynthesis to incorporate 14-&#x003b1;-methyl fecosterol in the cell membrane instead of ergosterol [<xref rid="B108-molecules-28-04183" ref-type="bibr">108</xref>]. Another frontline prescription for a systemic fungal infection is amphotericin B, a polyene macrolide antibiotic produced by the type I polyketide synthetase (PKS) of <italic toggle="yes">Streptomyces nodosus</italic> [<xref rid="B112-molecules-28-04183" ref-type="bibr">112</xref>]. The most accepted fungicidal mode of action is the pore creation model, in which polyenes bind to ergosterol to create an ion-channel-like complex and leak intracellular contents from the fungal cells. Other study models propose that amphotericin B acts similar to a hydrophobic &#x0201c;sponge&#x0201d; and specifically extracts ergosterol from the fungal membrane. Given the mode of action of polyenes is heavily dependent on ergosterol, resistance mechanisms have been developed by changing the fungal membrane sterol composition. Additionally, tolerance to oxidative stress may improve the fungi&#x02019;s ability to withstand exposure to amphotericin B [<xref rid="B113-molecules-28-04183" ref-type="bibr">113</xref>]. Considered as the last resort for antimicrobial-resistant or invasive fungal infections, echinocandins (e.g., echinocandins B) belong to the nonribosomal lipopeptide class produced by filamentous fungi. Echinocandins block the synthesis of 1,3-&#x003b2;-D-glucan, an important component of the fungal wall anatomy, causing significant stress and disruption of the cell wall integrity [<xref rid="B114-molecules-28-04183" ref-type="bibr">114</xref>,<xref rid="B115-molecules-28-04183" ref-type="bibr">115</xref>]. Mutations in FKS genes, which encode molecular targets of the enzyme 1,3-&#x003b2;-D-glucan synthase, are predominantly responsible for echinocandin resistance in <italic toggle="yes">Candida</italic> species [<xref rid="B108-molecules-28-04183" ref-type="bibr">108</xref>]. </p><p>The following drug leads with new antifungal targets merit special attention for pharmaceutical development. Firstly, sordarins (e.g., <bold>94</bold>), a class of tetracyclic diterpene antibiotics first discovered in 1969, are obtained from various natural sources, mostly from different fungi, and have varied structural components. By inhibiting the activity of fungal ribosomes and elongation factor 2, both of which are absent in mammalian cells, sordarins specifically impede the production of fungal proteins. However, no obvious candidates have been reported for clinical development and clinical trials [<xref rid="B116-molecules-28-04183" ref-type="bibr">116</xref>,<xref rid="B117-molecules-28-04183" ref-type="bibr">117</xref>]. Secondly, heat-stable antifungal factor (HSAF) (<bold>17</bold> in <xref rid="molecules-28-04183-f002" ref-type="fig">Figure 2</xref>), a tetramic-acid-containing macrolactam encoded by a PKS-NRPS hybrid gene cluster from <italic toggle="yes">Lysobacter enzymogenes</italic> C3, demonstrates strong activity in a wide range of fungi [<xref rid="B118-molecules-28-04183" ref-type="bibr">118</xref>]. The antifungal mode of action and biosynthesis regulation factors were later thoroughly investigated by Prof. Du&#x02019;s lab; they found that HSAF inhibits the production of fungal sphingolipids by specifically targeting ceramide synthases of filamentous fungi which do not present in mammals and plants. Additionally, HSAF induced ROS-medicated apoptosis in <italic toggle="yes">Candida albicans</italic> and significantly reduced the fungal burden in a murine model [<xref rid="B119-molecules-28-04183" ref-type="bibr">119</xref>,<xref rid="B120-molecules-28-04183" ref-type="bibr">120</xref>]. Thirdly, turbinmicin (<bold>14</bold>), which we discussed previously as a great candidate from the polyketide class for multidrug-resistant fungal infection. Mode-of-action studies suggested that turbinmicin targets fungal-specific Sec14 of the vesicular trafficking pathway, in contrast to other antifungal drugs. In addition to its potent efficacy in vitro and in vivo, the low toxicity and well-tolerant dosage of turbinmicin pave the way for its imminent preclinical study and translational development [<xref rid="B27-molecules-28-04183" ref-type="bibr">27</xref>].</p></sec></sec><sec id="sec4-molecules-28-04183"><title>4. Conclusions</title><p>This article reviews the literature from 2002 to 2022, focusing on five classes of antimicrobial agents discovered from natural sources or inspired by natural products. We examined the mechanisms of antimicrobial resistance (AMR) and reviewed the modes of action of promising antimicrobial drug leads. Moreover, we emphatically discussed the studies where various genome mining approaches were combined with either traditional natural product research technologies or state-of-the-art multidisciplinary technologies. </p><p>Although natural products exhibit a high degree of diverse stereochemistry, their biosynthetic enzymes are highly conserved and can be used to screen biosynthetic strains and their corresponding types of natural product compounds. Nowadays, genomic sequencing generates massive data and has become an integral part of modern biotechnological research. Its rapid growth has led to the development of bioinformatics tools that can analyze this information. The accumulative biosynthetic pathway research of numerous known compounds has assisted the development of algorithms to predict the enzymatic assembly lines (e.g., PKS and NRPS) and the structures of NPs derived from gene sequences. In addition to searching for NP biosynthesis enzymes, other mining approaches include (1) phylogeny-based excavation, (2) regulator screening, (3) tailored enzyme screening, (4) untargeted metabolomics, etc. Moreover, synthetic biology, molecular biology, and advanced analytical technologies are often integrated into today&#x02019;s natural product discovery strategies. These new approaches have armed researchers with the necessary tools for speedy and efficient novel antibiotic discovery, to fight against antimicrobial-resistant infections, and to stay ahead of pathogen evolution. </p><p>In addition to pouring resources into the development of new antibiotics, an in-depth understanding of antibiotic modes of action is needed to prescribe the relevant drug. Combinational therapy using antibiotics with different modes of action will also maximize efficacy. Furthermore, the explicit and detailed regulation of antimicrobial usage in healthcare settings worldwide as well as in the agriculture and animal husbandry industries is important to minimize or slow the spread of antimicrobial resistance.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Y.Y.: literature research, manuscript writing, and original draft preparation. M.G.C.K.: literature research and manuscript writing. M.R.M.-R.: reviewing and editing. Y.H.: reviewing and supervision. All authors have read and agreed to the published version of the manuscript. </p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no known competing financial or personal interests.</p></notes><ref-list><title>References</title><ref id="B1-molecules-28-04183"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micarelli</surname><given-names>I.</given-names></name>
<name><surname>Paine</surname><given-names>R.</given-names></name>
<name><surname>Giostra</surname><given-names>C.</given-names></name>
<name><surname>Tafuri</surname><given-names>M.A.</given-names></name>
<name><surname>Profico</surname><given-names>A.</given-names></name>
<name><surname>Boggioni</surname><given-names>M.</given-names></name>
<name><surname>Di Vincenzo</surname><given-names>F.</given-names></name>
<name><surname>Massani</surname><given-names>D.</given-names></name>
<name><surname>Papini</surname><given-names>A.</given-names></name>
<name><surname>Manzi</surname><given-names>G.</given-names></name>
</person-group><article-title>Survival to amputation in pre-antibiotic era: A case study from a Longobard necropolis (6th-8th centuries AD)</article-title><source>J. Anthropol. Sci.</source><year>2018</year><volume>96</volume><fpage>185</fpage><lpage>200</lpage><?supplied-pmid 29717991?><pub-id pub-id-type="pmid">29717991</pub-id></element-citation></ref><ref id="B2-molecules-28-04183"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>O&#x02019;Neill</surname><given-names>J.</given-names></name>
</person-group><source>Tackling Drug-Resistant Infections Globally: Final Report and Recommendations</source><publisher-name>Government of the United Kingdom</publisher-name><publisher-loc>London, UK</publisher-loc><year>2016</year></element-citation></ref><ref id="B3-molecules-28-04183"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><source>Antibiotic Resistance Threats in the United States 2019</source><publisher-name>Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion, Antibiotic Resistance Coordination; Strategy Unit within the Division of Healthcare Quality Promotion, U.S. Department of Health and Human Services</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B4-molecules-28-04183"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CDC</collab>
</person-group><source>COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022</source><publisher-name>Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion, U.S. Department of Health and Human Services</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B5-molecules-28-04183"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clardy</surname><given-names>J.</given-names></name>
<name><surname>Fischbach</surname><given-names>M.A.</given-names></name>
<name><surname>Walsh</surname><given-names>C.T.</given-names></name>
</person-group><article-title>New antibiotics from bacterial natural products</article-title><source>Nat. Biotechnol.</source><year>2006</year><volume>24</volume><fpage>1541</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1038/nbt1266</pub-id><?supplied-pmid 17160060?><pub-id pub-id-type="pmid">17160060</pub-id></element-citation></ref><ref id="B6-molecules-28-04183"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.H.</given-names></name>
<name><surname>Ung</surname><given-names>P.M.</given-names></name>
<name><surname>Zajkowski</surname><given-names>J.</given-names></name>
<name><surname>Garneau-Tsodikova</surname><given-names>S.</given-names></name>
<name><surname>Sherman</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Automated genome mining for natural products</article-title><source>BMC Bioinform.</source><year>2009</year><volume>10</volume><elocation-id>185</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-185</pub-id><?supplied-pmid 19531248?><pub-id pub-id-type="pmid">19531248</pub-id></element-citation></ref><ref id="B7-molecules-28-04183"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Albarano</surname><given-names>L.</given-names></name>
<name><surname>Esposito</surname><given-names>R.</given-names></name>
<name><surname>Ruocco</surname><given-names>N.</given-names></name>
<name><surname>Costantini</surname><given-names>M.</given-names></name>
</person-group><article-title>Genome mining as new challenge in natural products discovery</article-title><source>Mar. Drugs</source><year>2020</year><volume>18</volume><elocation-id>199</elocation-id><pub-id pub-id-type="doi">10.3390/md18040199</pub-id><pub-id pub-id-type="pmid">32283638</pub-id></element-citation></ref><ref id="B8-molecules-28-04183"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baltz</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Genome mining for drug discovery: Progress at the front end</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2021</year><volume>48</volume><fpage>kuab044</fpage><pub-id pub-id-type="doi">10.1093/jimb/kuab044</pub-id><pub-id pub-id-type="pmid">34279640</pub-id></element-citation></ref><ref id="B9-molecules-28-04183"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banskota</surname><given-names>A.H.</given-names></name>
<name><surname>McAlpine</surname><given-names>J.B.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>D.</given-names></name>
<name><surname>Ibrahim</surname><given-names>A.</given-names></name>
<name><surname>Aouidate</surname><given-names>M.</given-names></name>
<name><surname>Piraee</surname><given-names>M.</given-names></name>
<name><surname>Alarco</surname><given-names>A.-M.</given-names></name>
<name><surname>Farnet</surname><given-names>C.M.</given-names></name>
<name><surname>Zazopoulos</surname><given-names>E.</given-names></name>
</person-group><article-title>Genomic analyses lead to novel secondary metabolites</article-title><source>J. Antiobiot.</source><year>2006</year><volume>59</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/ja.2006.74</pub-id></element-citation></ref><ref id="B10-molecules-28-04183"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>B.</given-names></name>
</person-group><article-title>Polyketide biosynthesis beyond the type I, II and III polyketide synthase paradigms</article-title><source>Curr. Opin. Chem. Biol.</source><year>2003</year><volume>7</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/S1367-5931(03)00020-6</pub-id><pub-id pub-id-type="pmid">12714063</pub-id></element-citation></ref><ref id="B11-molecules-28-04183"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Helfrich</surname><given-names>E.J.N.</given-names></name>
<name><surname>Reiter</surname><given-names>S.</given-names></name>
<name><surname>Piel</surname><given-names>J.</given-names></name>
</person-group><article-title>Recent advances in genome-based polyketide discovery</article-title><source>Curr. Opin. Biotechnol.</source><year>2014</year><volume>29</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2014.03.004</pub-id><pub-id pub-id-type="pmid">24762576</pub-id></element-citation></ref><ref id="B12-molecules-28-04183"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bessa</surname><given-names>L.J.</given-names></name>
<name><surname>Buttachon</surname><given-names>S.</given-names></name>
<name><surname>Dethoup</surname><given-names>T.</given-names></name>
<name><surname>Martins</surname><given-names>R.</given-names></name>
<name><surname>Vasconcelos</surname><given-names>V.</given-names></name>
<name><surname>Kijjoa</surname><given-names>A.</given-names></name>
<name><surname>Martins da Costa</surname><given-names>P.</given-names></name>
</person-group><article-title>Neofiscalin A and fiscalin C are potential novel indole alkaloid alternatives for the treatment of multidrug-resistant Gram-positive bacterial infections</article-title><source>FEMS Microbiol. Lett.</source><year>2016</year><volume>363</volume><fpage>fnw150</fpage><pub-id pub-id-type="doi">10.1093/femsle/fnw150</pub-id><pub-id pub-id-type="pmid">27268269</pub-id></element-citation></ref><ref id="B13-molecules-28-04183"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hensler</surname><given-names>M.E.</given-names></name>
<name><surname>Jang</surname><given-names>K.H.</given-names></name>
<name><surname>Thienphrapa</surname><given-names>W.</given-names></name>
<name><surname>Vuong</surname><given-names>L.</given-names></name>
<name><surname>Tran</surname><given-names>D.N.</given-names></name>
<name><surname>Soubih</surname><given-names>E.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Haste</surname><given-names>N.M.</given-names></name>
<name><surname>Cunningham</surname><given-names>M.L.</given-names></name>
<name><surname>Kwan</surname><given-names>B.P.</given-names></name>
<etal/>
</person-group><article-title>Anthracimycin activity against contemporary methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>J. Antibiot.</source><year>2014</year><volume>67</volume><fpage>549</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.36</pub-id></element-citation></ref><ref id="B14-molecules-28-04183"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panter</surname><given-names>F.</given-names></name>
<name><surname>Krug</surname><given-names>D.</given-names></name>
<name><surname>Baumann</surname><given-names>S.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>R.</given-names></name>
</person-group><article-title>Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria</article-title><source>Chem. Sci.</source><year>2018</year><volume>9</volume><fpage>4898</fpage><lpage>4908</lpage><pub-id pub-id-type="doi">10.1039/C8SC01325J</pub-id><?supplied-pmid 29910943?><pub-id pub-id-type="pmid">29910943</pub-id></element-citation></ref><ref id="B15-molecules-28-04183"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Millan-Aguinaga</surname><given-names>N.</given-names></name>
<name><surname>Zhang</surname><given-names>J.J.</given-names></name>
<name><surname>O&#x02019;Neill</surname><given-names>E.C.</given-names></name>
<name><surname>Ugalde</surname><given-names>J.A.</given-names></name>
<name><surname>Jensen</surname><given-names>P.R.</given-names></name>
<name><surname>Mantovani</surname><given-names>S.M.</given-names></name>
<name><surname>Moore</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Identification of thiotetronic acid antibiotic biosynthetic pathways by target-directed genome mining</article-title><source>ACS Chem. Biol.</source><year>2015</year><volume>10</volume><fpage>2841</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00658</pub-id><pub-id pub-id-type="pmid">26458099</pub-id></element-citation></ref><ref id="B16-molecules-28-04183"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thong</surname><given-names>W.L.</given-names></name>
<name><surname>Shin-ya</surname><given-names>K.</given-names></name>
<name><surname>Nishiyama</surname><given-names>M.</given-names></name>
<name><surname>Kuzuyama</surname><given-names>T.</given-names></name>
</person-group><article-title>Discovery of an antibacterial isoindolinone-containing tetracyclic polyketide by cryptic gene activation and characterization of its biosynthetic gene cluster</article-title><source>ACS Chem. Biol.</source><year>2018</year><volume>13</volume><fpage>2615</fpage><lpage>2622</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b00553</pub-id><pub-id pub-id-type="pmid">30080389</pub-id></element-citation></ref><ref id="B17-molecules-28-04183"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuoco</surname><given-names>D.</given-names></name>
</person-group><article-title>Classification framework and chemical biology of tetracycline-structure-based drugs</article-title><source>Antibiotics</source><year>2012</year><volume>1</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3390/antibiotics1010001</pub-id><?supplied-pmid 27029415?><pub-id pub-id-type="pmid">27029415</pub-id></element-citation></ref><ref id="B18-molecules-28-04183"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.X.</given-names></name>
<name><surname>Chen</surname><given-names>Y.Y.</given-names></name>
<name><surname>Ge</surname><given-names>L.</given-names></name>
<name><surname>Fang</surname><given-names>T.T.</given-names></name>
<name><surname>Meng</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Fang</surname><given-names>X.Y.</given-names></name>
<name><surname>Ni</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>Y.Y.</given-names></name>
<etal/>
</person-group><article-title>PCR screening reveals considerable unexploited biosynthetic potential of ansamycins and a mysterious family of AHBA-containing natural products in actinomycetes</article-title><source>J. Appl. Microbiol.</source><year>2013</year><volume>115</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/jam.12217</pub-id><?supplied-pmid 23594089?><pub-id pub-id-type="pmid">23594089</pub-id></element-citation></ref><ref id="B19-molecules-28-04183"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Activating a cryptic ansamycin biosynthetic gene cluster to produce three new naphthalenic octaketide ansamycins with n-pentyl and n-butyl side chains</article-title><source>Org. Lett.</source><year>2015</year><volume>17</volume><fpage>3706</fpage><lpage>3709</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.5b01686</pub-id><pub-id pub-id-type="pmid">26167742</pub-id></element-citation></ref><ref id="B20-molecules-28-04183"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Tang</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Neoansamycins from <italic toggle="yes">Streptomyces</italic> sp. LZ35</article-title><source>RSC Adv.</source><year>2017</year><volume>7</volume><fpage>35460</fpage><lpage>35465</lpage><pub-id pub-id-type="doi">10.1039/C7RA06339C</pub-id></element-citation></ref><ref id="B21-molecules-28-04183"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adnani</surname><given-names>N.</given-names></name>
<name><surname>Chevrette</surname><given-names>M.G.</given-names></name>
<name><surname>Adibhatla</surname><given-names>S.N.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Braun</surname><given-names>D.R.</given-names></name>
<name><surname>Nelson</surname><given-names>J.</given-names></name>
<name><surname>Simpkins</surname><given-names>S.W.</given-names></name>
<name><surname>McDonald</surname><given-names>B.R.</given-names></name>
<name><surname>Myers</surname><given-names>C.L.</given-names></name>
<etal/>
</person-group><article-title>Coculture of marine invertebrate-associated bacteria and interdisciplinary technologies enable biosynthesis and discovery of a new antibiotic, Keyicin</article-title><source>ACS Chem. Biol.</source><year>2017</year><volume>12</volume><fpage>3093</fpage><lpage>3102</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00688</pub-id><pub-id pub-id-type="pmid">29121465</pub-id></element-citation></ref><ref id="B22-molecules-28-04183"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chanana</surname><given-names>S.</given-names></name>
<name><surname>Thomas</surname><given-names>C.S.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Rajski</surname><given-names>S.R.</given-names></name>
<name><surname>Bugni</surname><given-names>T.S.</given-names></name>
</person-group><article-title>hcapca: Automated hierarchical clustering and principal component analysis of large metabolomic datasets in R</article-title><source>Metabolites</source><year>2020</year><volume>10</volume><elocation-id>297</elocation-id><pub-id pub-id-type="doi">10.3390/metabo10070297</pub-id><pub-id pub-id-type="pmid">32708222</pub-id></element-citation></ref><ref id="B23-molecules-28-04183"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brklja&#x0010d;a</surname><given-names>R.</given-names></name>
<name><surname>Urban</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent advancements in HPLC-NMR and applications for natural product profiling and identification</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2011</year><volume>34</volume><fpage>1063</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1080/10826076.2011.587748</pub-id></element-citation></ref><ref id="B24-molecules-28-04183"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Danelius</surname><given-names>E.</given-names></name>
<name><surname>Halaby</surname><given-names>S.</given-names></name>
<name><surname>van der Donk</surname><given-names>W.A.</given-names></name>
<name><surname>Gonen</surname><given-names>T.</given-names></name>
</person-group><article-title>MicroED in natural product and small molecule research</article-title><source>Nat. Prod. Rep.</source><year>2021</year><volume>38</volume><fpage>423</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1039/D0NP00035C</pub-id><pub-id pub-id-type="pmid">32939523</pub-id></element-citation></ref><ref id="B25-molecules-28-04183"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>P.E.</given-names></name>
</person-group><article-title>NMR of natural products as potential drugs</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>3763</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26123763</pub-id><pub-id pub-id-type="pmid">34205539</pub-id></element-citation></ref><ref id="B26-molecules-28-04183"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>L.J.</given-names></name>
<name><surname>Ohashi</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Tan</surname><given-names>D.</given-names></name>
<name><surname>Asay</surname><given-names>M.</given-names></name>
<name><surname>Cascio</surname><given-names>D.</given-names></name>
<name><surname>Rodriguez</surname><given-names>J.A.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Nelson</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Prospecting for natural products by genome mining and microcrystal electron diffraction</article-title><source>Nat. Chem. Biol.</source><year>2021</year><volume>17</volume><fpage>872</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1038/s41589-021-00834-2</pub-id><pub-id pub-id-type="pmid">34312563</pub-id></element-citation></ref><ref id="B27-molecules-28-04183"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Braun</surname><given-names>D.R.</given-names></name>
<name><surname>Ericksen</surname><given-names>S.S.</given-names></name>
<name><surname>Piotrowski</surname><given-names>J.S.</given-names></name>
<name><surname>Nelson</surname><given-names>J.</given-names></name>
<name><surname>Peng</surname><given-names>J.</given-names></name>
<name><surname>Ananiev</surname><given-names>G.E.</given-names></name>
<name><surname>Chanana</surname><given-names>S.</given-names></name>
<name><surname>Barns</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>A marine microbiome antifungal targets urgent-threat drug-resistant fungi</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>974</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1126/science.abd6919</pub-id><pub-id pub-id-type="pmid">33214279</pub-id></element-citation></ref><ref id="B28-molecules-28-04183"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pidot</surname><given-names>S.</given-names></name>
<name><surname>Ishida</surname><given-names>K.</given-names></name>
<name><surname>Cyrulies</surname><given-names>M.</given-names></name>
<name><surname>Hertweck</surname><given-names>C.</given-names></name>
</person-group><article-title>Discovery of clostrubin, an exceptional polyphenolic polyketide antibiotic from a strictly anaerobic bacterium</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2014</year><volume>53</volume><fpage>7856</fpage><lpage>7859</lpage><pub-id pub-id-type="doi">10.1002/anie.201402632</pub-id><pub-id pub-id-type="pmid">24827417</pub-id></element-citation></ref><ref id="B29-molecules-28-04183"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shabuer</surname><given-names>G.</given-names></name>
<name><surname>Ishida</surname><given-names>K.</given-names></name>
<name><surname>Pidot</surname><given-names>S.J.</given-names></name>
<name><surname>Roth</surname><given-names>M.</given-names></name>
<name><surname>Dahse</surname><given-names>H.-M.</given-names></name>
<name><surname>Hertweck</surname><given-names>C.</given-names></name>
</person-group><article-title>Plant pathogenic anaerobic bacteria use aromatic polyketides to access aerobic territory</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>670</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1126/science.aac9990</pub-id><pub-id pub-id-type="pmid">26542569</pub-id></element-citation></ref><ref id="B30-molecules-28-04183"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000fc;ssmuth</surname><given-names>R.D.</given-names></name>
<name><surname>Mainz</surname><given-names>A.</given-names></name>
</person-group><article-title>Nonribosomal Peptide Synthesis-Principles and Prospects</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2017</year><volume>56</volume><fpage>3770</fpage><lpage>3821</lpage><pub-id pub-id-type="doi">10.1002/anie.201609079</pub-id><pub-id pub-id-type="pmid">28323366</pub-id></element-citation></ref><ref id="B31-molecules-28-04183"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Engelhardt</surname><given-names>K.</given-names></name>
<name><surname>Degnes</surname><given-names>K.F.</given-names></name>
<name><surname>Kemmler</surname><given-names>M.</given-names></name>
<name><surname>Bredholt</surname><given-names>H.</given-names></name>
<name><surname>Fjaervik</surname><given-names>E.</given-names></name>
<name><surname>Klinkenberg</surname><given-names>G.</given-names></name>
<name><surname>Sletta</surname><given-names>H.</given-names></name>
<name><surname>Ellingsen</surname><given-names>T.E.</given-names></name>
<name><surname>Zotchev</surname><given-names>S.B.</given-names></name>
</person-group><article-title>Production of a new thiopeptide antibiotic, TP-1161, by a marine <italic toggle="yes">Nocardiopsis</italic> species</article-title><source>Appl. Environ. Microbiol.</source><year>2010</year><volume>76</volume><fpage>4969</fpage><lpage>4976</lpage><pub-id pub-id-type="doi">10.1128/AEM.00741-10</pub-id><?supplied-pmid 20562278?><pub-id pub-id-type="pmid">20562278</pub-id></element-citation></ref><ref id="B32-molecules-28-04183"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Shukla</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Weingarth</surname><given-names>M.</given-names></name>
<name><surname>Breukink</surname><given-names>E.</given-names></name>
<name><surname>Kuipers</surname><given-names>O.P.</given-names></name>
</person-group><article-title>Brevibacillin 2V, a novel antimicrobial lipopeptide with an exceptionally low hemolytic activity</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><fpage>693725</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.693725</pub-id><pub-id pub-id-type="pmid">34220785</pub-id></element-citation></ref><ref id="B33-molecules-28-04183"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>de Jong</surname><given-names>A.</given-names></name>
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Kuipers</surname><given-names>O.P.</given-names></name>
</person-group><article-title>Identification, isolation, and characterization of medipeptins, antimicrobial peptides from <italic toggle="yes">Pseudomonas mediterranea</italic> EDOX</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><fpage>732771</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.732771</pub-id><pub-id pub-id-type="pmid">34594316</pub-id></element-citation></ref><ref id="B34-molecules-28-04183"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hover</surname><given-names>B.M.</given-names></name>
<name><surname>Kim</surname><given-names>S.H.</given-names></name>
<name><surname>Katz</surname><given-names>M.</given-names></name>
<name><surname>Charlop-Powers</surname><given-names>Z.</given-names></name>
<name><surname>Owen</surname><given-names>J.G.</given-names></name>
<name><surname>Ternei</surname><given-names>M.A.</given-names></name>
<name><surname>Maniko</surname><given-names>J.</given-names></name>
<name><surname>Estrela</surname><given-names>A.B.</given-names></name>
<name><surname>Molina</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens</article-title><source>Nat. Microbiol.</source><year>2018</year><volume>3</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0110-1</pub-id><pub-id pub-id-type="pmid">29434326</pub-id></element-citation></ref><ref id="B35-molecules-28-04183"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamanaka</surname><given-names>K.</given-names></name>
<name><surname>Reynolds</surname><given-names>K.A.</given-names></name>
<name><surname>Kersten</surname><given-names>R.D.</given-names></name>
<name><surname>Ryan</surname><given-names>K.S.</given-names></name>
<name><surname>Gonzalez</surname><given-names>D.J.</given-names></name>
<name><surname>Nizet</surname><given-names>V.</given-names></name>
<name><surname>Dorrestein</surname><given-names>P.C.</given-names></name>
<name><surname>Moore</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>1957</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1073/pnas.1319584111</pub-id><pub-id pub-id-type="pmid">24449899</pub-id></element-citation></ref><ref id="B36-molecules-28-04183"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>K.A.</given-names></name>
<name><surname>Luhavaya</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Dahesh</surname><given-names>S.</given-names></name>
<name><surname>Nizet</surname><given-names>V.</given-names></name>
<name><surname>Yamanaka</surname><given-names>K.</given-names></name>
<name><surname>Moore</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Isolation and structure elucidation of lipopeptide antibiotic taromycin B from the activated taromycin biosynthetic gene cluster</article-title><source>J. Antibiot. (Tokyo)</source><year>2018</year><volume>71</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.146</pub-id><pub-id pub-id-type="pmid">29184121</pub-id></element-citation></ref><ref id="B37-molecules-28-04183"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ling</surname><given-names>L.L.</given-names></name>
<name><surname>Schneider</surname><given-names>T.</given-names></name>
<name><surname>Peoples</surname><given-names>A.J.</given-names></name>
<name><surname>Spoering</surname><given-names>A.L.</given-names></name>
<name><surname>Engels</surname><given-names>I.</given-names></name>
<name><surname>Conlon</surname><given-names>B.P.</given-names></name>
<name><surname>Mueller</surname><given-names>A.</given-names></name>
<name><surname>Sch&#x000e4;berle</surname><given-names>T.F.</given-names></name>
<name><surname>Hughes</surname><given-names>D.E.</given-names></name>
<name><surname>Epstein</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A new antibiotic kills pathogens without detectable resistance</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/nature14098</pub-id><?supplied-pmid 25561178?><pub-id pub-id-type="pmid">25561178</pub-id></element-citation></ref><ref id="B38-molecules-28-04183"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zipperer</surname><given-names>A.</given-names></name>
<name><surname>Konnerth</surname><given-names>M.C.</given-names></name>
<name><surname>Laux</surname><given-names>C.</given-names></name>
<name><surname>Berscheid</surname><given-names>A.</given-names></name>
<name><surname>Janek</surname><given-names>D.</given-names></name>
<name><surname>Weidenmaier</surname><given-names>C.</given-names></name>
<name><surname>Burian</surname><given-names>M.</given-names></name>
<name><surname>Schilling</surname><given-names>N.A.</given-names></name>
<name><surname>Slavetinsky</surname><given-names>C.</given-names></name>
<name><surname>Marschal</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Human commensals producing a novel antibiotic impair pathogen colonization</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>511</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/nature18634</pub-id><pub-id pub-id-type="pmid">27466123</pub-id></element-citation></ref><ref id="B39-molecules-28-04183"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Koirala</surname><given-names>B.</given-names></name>
<name><surname>Hernandez</surname><given-names>Y.</given-names></name>
<name><surname>Zimmerman</surname><given-names>M.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Perlin</surname><given-names>D.S.</given-names></name>
<name><surname>Brady</surname><given-names>S.F.</given-names></name>
</person-group><article-title>A naturally inspired antibiotic to target multidrug-resistant pathogens</article-title><source>Nature</source><year>2022</year><volume>601</volume><fpage>606</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04264-x</pub-id><pub-id pub-id-type="pmid">34987225</pub-id></element-citation></ref><ref id="B40-molecules-28-04183"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>J.</given-names></name>
<name><surname>Vila-Farres</surname><given-names>X.</given-names></name>
<name><surname>Inoyama</surname><given-names>D.</given-names></name>
<name><surname>Ternei</surname><given-names>M.</given-names></name>
<name><surname>Cohen</surname><given-names>L.J.</given-names></name>
<name><surname>Gordon</surname><given-names>E.A.</given-names></name>
<name><surname>Reddy</surname><given-names>B.V.</given-names></name>
<name><surname>Charlop-Powers</surname><given-names>Z.</given-names></name>
<name><surname>Zebroski</surname><given-names>H.A.</given-names></name>
<name><surname>Gallardo-Macias</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Discovery of MRSA active antibiotics using primary sequence from the human microbiome</article-title><source>Nat. Chem. Biol.</source><year>2016</year><volume>12</volume><fpage>1004</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2207</pub-id><?supplied-pmid 27748750?><pub-id pub-id-type="pmid">27748750</pub-id></element-citation></ref><ref id="B41-molecules-28-04183"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vila-Farres</surname><given-names>X.</given-names></name>
<name><surname>Chu</surname><given-names>J.</given-names></name>
<name><surname>Ternei</surname><given-names>M.A.</given-names></name>
<name><surname>Lemetre</surname><given-names>C.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Perlin</surname><given-names>D.S.</given-names></name>
<name><surname>Brady</surname><given-names>S.F.</given-names></name>
</person-group><article-title>An optimized synthetic-bioinformatic natural product antibiotic sterilizes multidrug-resistant <italic toggle="yes">Acinetobacter baumannii</italic>-infected wounds</article-title><source>mSphere</source><year>2018</year><volume>3</volume><fpage>e00528-17</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00528-17</pub-id><pub-id pub-id-type="pmid">29404414</pub-id></element-citation></ref><ref id="B42-molecules-28-04183"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vila-Farres</surname><given-names>X.</given-names></name>
<name><surname>Chu</surname><given-names>J.</given-names></name>
<name><surname>Inoyama</surname><given-names>D.</given-names></name>
<name><surname>Ternei</surname><given-names>M.A.</given-names></name>
<name><surname>Lemetre</surname><given-names>C.</given-names></name>
<name><surname>Cohen</surname><given-names>L.J.</given-names></name>
<name><surname>Cho</surname><given-names>W.</given-names></name>
<name><surname>Reddy</surname><given-names>B.V.B.</given-names></name>
<name><surname>Zebroski</surname><given-names>H.A.</given-names></name>
<name><surname>Freundlich</surname><given-names>J.S.</given-names></name>
<etal/>
</person-group><article-title>Antimicrobials inspired by nonribosomal peptide synthetase gene clusters</article-title><source>J. Am. Chem. Soc.</source><year>2017</year><volume>139</volume><fpage>1404</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1021/jacs.6b11861</pub-id><?supplied-pmid 28055186?><pub-id pub-id-type="pmid">28055186</pub-id></element-citation></ref><ref id="B43-molecules-28-04183"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Cao</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Ren</surname><given-names>J.</given-names></name>
<name><surname>Xiang</surname><given-names>H.</given-names></name>
<name><surname>Lin</surname><given-names>S.</given-names></name>
<name><surname>Ju</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Design and biosynthesis of dimeric alboflavusins with biaryl linkages via regiospecific C&#x02013;C bond coupling</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>18009</fpage><lpage>18015</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b10136</pub-id><pub-id pub-id-type="pmid">30516971</pub-id></element-citation></ref><ref id="B44-molecules-28-04183"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poorinmohammad</surname><given-names>N.</given-names></name>
<name><surname>Bagheban-Shemirani</surname><given-names>R.</given-names></name>
<name><surname>Hamedi</surname><given-names>J.</given-names></name>
</person-group><article-title>Genome mining for ribosomally synthesised and post-translationally modified peptides (RiPPs) reveals undiscovered bioactive potentials of actinobacteria</article-title><source>Antonie Van Leeuwenhoek</source><year>2019</year><volume>112</volume><fpage>1477</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1007/s10482-019-01276-6</pub-id><?supplied-pmid 31123844?><pub-id pub-id-type="pmid">31123844</pub-id></element-citation></ref><ref id="B45-molecules-28-04183"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Der Torossian Torres</surname><given-names>M.</given-names></name>
<name><surname>de la Fuente-Nunez</surname><given-names>C.</given-names></name>
</person-group><article-title>Reprogramming biological peptides to combat infectious diseases</article-title><source>Chem. Commun.</source><year>2019</year><volume>55</volume><fpage>15020</fpage><lpage>15032</lpage><pub-id pub-id-type="doi">10.1039/C9CC07898C</pub-id></element-citation></ref><ref id="B46-molecules-28-04183"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donia</surname><given-names>M.S.</given-names></name>
<name><surname>Cimermancic</surname><given-names>P.</given-names></name>
<name><surname>Schulze</surname><given-names>C.J.</given-names></name>
<name><surname>Wieland Brown</surname><given-names>L.C.</given-names></name>
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Mitreva</surname><given-names>M.</given-names></name>
<name><surname>Clardy</surname><given-names>J.</given-names></name>
<name><surname>Linington</surname><given-names>R.G.</given-names></name>
</person-group><article-title>A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>1402</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.032</pub-id><pub-id pub-id-type="pmid">25215495</pub-id></element-citation></ref><ref id="B47-molecules-28-04183"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dischinger</surname><given-names>J.</given-names></name>
<name><surname>Josten</surname><given-names>M.</given-names></name>
<name><surname>Szekat</surname><given-names>C.</given-names></name>
<name><surname>Sahl</surname><given-names>H.G.</given-names></name>
<name><surname>Bierbaum</surname><given-names>G.</given-names></name>
</person-group><article-title>Production of the novel two-peptide lantibiotic lichenicidin by <italic toggle="yes">Bacillus licheniformis</italic> DSM 13</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e6788</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006788</pub-id><pub-id pub-id-type="pmid">19707558</pub-id></element-citation></ref><ref id="B48-molecules-28-04183"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shenkarev</surname><given-names>Z.O.</given-names></name>
<name><surname>Finkina</surname><given-names>E.I.</given-names></name>
<name><surname>Nurmukhamedova</surname><given-names>E.K.</given-names></name>
<name><surname>Balandin</surname><given-names>S.V.</given-names></name>
<name><surname>Mineev</surname><given-names>K.S.</given-names></name>
<name><surname>Nadezhdin</surname><given-names>K.D.</given-names></name>
<name><surname>Yakimenko</surname><given-names>Z.A.</given-names></name>
<name><surname>Tagaev</surname><given-names>A.A.</given-names></name>
<name><surname>Temirov</surname><given-names>Y.V.</given-names></name>
<name><surname>Arseniev</surname><given-names>A.S.</given-names></name>
<etal/>
</person-group><article-title>Isolation, structure elucidation, and synergistic antibacterial activity of a novel two-component lantibiotic lichenicidin from <italic toggle="yes">Bacillus licheniformis</italic> VK21</article-title><source>Biochemistry</source><year>2010</year><volume>49</volume><fpage>6462</fpage><lpage>6472</lpage><pub-id pub-id-type="doi">10.1021/bi100871b</pub-id><?supplied-pmid 20578714?><pub-id pub-id-type="pmid">20578714</pub-id></element-citation></ref><ref id="B49-molecules-28-04183"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hudson</surname><given-names>G.A.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Tietz</surname><given-names>J.I.</given-names></name>
<name><surname>Mitchell</surname><given-names>D.A.</given-names></name>
<name><surname>van der Donk</surname><given-names>W.A.</given-names></name>
</person-group><article-title>In vitro biosynthesis of the core scaffold of the thiopeptide thiomuracin</article-title><source>J. Am. Chem. Soc.</source><year>2015</year><volume>137</volume><fpage>16012</fpage><lpage>16015</lpage><pub-id pub-id-type="doi">10.1021/jacs.5b10194</pub-id><pub-id pub-id-type="pmid">26675417</pub-id></element-citation></ref><ref id="B50-molecules-28-04183"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaweewan</surname><given-names>I.</given-names></name>
<name><surname>Hemmi</surname><given-names>H.</given-names></name>
<name><surname>Komaki</surname><given-names>H.</given-names></name>
<name><surname>Harada</surname><given-names>S.</given-names></name>
<name><surname>Kodani</surname><given-names>S.</given-names></name>
</person-group><article-title>Isolation and structure determination of a new lasso peptide specialicin based on genome mining</article-title><source>Bioorg. Med. Chem.</source><year>2018</year><volume>26</volume><fpage>6050</fpage><lpage>6055</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2018.11.007</pub-id><?supplied-pmid 30448257?><pub-id pub-id-type="pmid">30448257</pub-id></element-citation></ref><ref id="B51-molecules-28-04183"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gavrish</surname><given-names>E.</given-names></name>
<name><surname>Clarissa</surname><given-names>S.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Kandror</surname><given-names>O.</given-names></name>
<name><surname>Spoering</surname><given-names>A.</given-names></name>
<name><surname>Peoples</surname><given-names>A.</given-names></name>
<name><surname>Ling</surname><given-names>L.</given-names></name>
<name><surname>Fetterman</surname><given-names>A.</given-names></name>
<name><surname>Hughes</surname><given-names>D.</given-names></name>
<name><surname>Bissell</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Lassomycin, a ribosomally synthesized cyclic peptide, kills <italic toggle="yes">Mycobacterium tuberculosis</italic> by targeting the ATP-dependent protease ClpC1P1P2</article-title><source>Chem. Biol.</source><year>2014</year><volume>21</volume><fpage>509</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.01.014</pub-id><pub-id pub-id-type="pmid">24684906</pub-id></element-citation></ref><ref id="B52-molecules-28-04183"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheung-Lee</surname><given-names>W.L.</given-names></name>
<name><surname>Parry</surname><given-names>M.E.</given-names></name>
<name><surname>Jaramillo Cartagena</surname><given-names>A.</given-names></name>
<name><surname>Darst</surname><given-names>S.A.</given-names></name>
<name><surname>Link</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Discovery and structure of the antimicrobial lasso peptide citrocin</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>6822</fpage><lpage>6830</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.006494</pub-id><pub-id pub-id-type="pmid">30846564</pub-id></element-citation></ref><ref id="B53-molecules-28-04183"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horbal</surname><given-names>L.</given-names></name>
<name><surname>Marques</surname><given-names>F.</given-names></name>
<name><surname>Nadmid</surname><given-names>S.</given-names></name>
<name><surname>Mendes</surname><given-names>M.V.</given-names></name>
<name><surname>Luzhetskyy</surname><given-names>A.</given-names></name>
</person-group><article-title>Secondary metabolites overproduction through transcriptional gene cluster refactoring</article-title><source>Metab. Eng.</source><year>2018</year><volume>49</volume><fpage>299</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.ymben.2018.09.010</pub-id><pub-id pub-id-type="pmid">30240601</pub-id></element-citation></ref><ref id="B54-molecules-28-04183"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimamura</surname><given-names>H.</given-names></name>
<name><surname>Gouda</surname><given-names>H.</given-names></name>
<name><surname>Nagai</surname><given-names>K.</given-names></name>
<name><surname>Hirose</surname><given-names>T.</given-names></name>
<name><surname>Ichioka</surname><given-names>M.</given-names></name>
<name><surname>Furuya</surname><given-names>Y.</given-names></name>
<name><surname>Kobayashi</surname><given-names>Y.</given-names></name>
<name><surname>Hirono</surname><given-names>S.</given-names></name>
<name><surname>Sunazuka</surname><given-names>T.</given-names></name>
<name><surname>&#x0014c;mura</surname><given-names>S.</given-names></name>
</person-group><article-title>Structure determination and total synthesis of bottromycin A2: A potent antibiotic against MRSA and VRE</article-title><source>Angew. Chem.</source><year>2009</year><volume>121</volume><fpage>932</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1002/ange.200804138</pub-id></element-citation></ref><ref id="B55-molecules-28-04183"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goto</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Claesen</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Bibb</surname><given-names>M.J.</given-names></name>
<name><surname>van der Donk</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Discovery of unique lanthionine synthetases reveals new mechanistic and evolutionary insights</article-title><source>PLoS Biol.</source><year>2010</year><volume>8</volume><elocation-id>e1000339</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000339</pub-id><?supplied-pmid 20351769?><pub-id pub-id-type="pmid">20351769</pub-id></element-citation></ref><ref id="B56-molecules-28-04183"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Staden</surname><given-names>A.D.P.</given-names></name>
<name><surname>van Zyl</surname><given-names>W.F.</given-names></name>
<name><surname>Trindade</surname><given-names>M.</given-names></name>
<name><surname>Dicks</surname><given-names>L.M.T.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
</person-group><article-title>Therapeutic application of lantibiotics and other lanthipeptides: Old and new findings</article-title><source>Appl. Environ. Microbiol.</source><year>2021</year><volume>87</volume><fpage>e0018621</fpage><pub-id pub-id-type="doi">10.1128/AEM.00186-21</pub-id><pub-id pub-id-type="pmid">33962984</pub-id></element-citation></ref><ref id="B57-molecules-28-04183"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Yin</surname><given-names>Z.</given-names></name>
<name><surname>Breukink</surname><given-names>E.</given-names></name>
<name><surname>Moll</surname><given-names>G.N.</given-names></name>
<name><surname>Kuipers</surname><given-names>O.P.</given-names></name>
</person-group><article-title>An engineered double lipid II binding motifs-containing lantibiotic displays potent and selective antimicrobial activity against <italic toggle="yes">Enterococcus faecium</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e02050-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.02050-19</pub-id><pub-id pub-id-type="pmid">32179527</pub-id></element-citation></ref><ref id="B58-molecules-28-04183"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>J.</given-names></name>
<name><surname>Guiza Beltran</surname><given-names>D.</given-names></name>
<name><surname>Schacht</surname><given-names>A.</given-names></name>
<name><surname>Wright</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
</person-group><article-title>Functional and structural analysis of Phenazine O-Methyltransferase LaPhzM from <italic toggle="yes">Lysobacter antibioticus</italic> OH13 and one-pot enzymatic synthesis of the antibiotic myxin</article-title><source>ACS Chem. Biol.</source><year>2018</year><volume>13</volume><fpage>1003</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b00062</pub-id><pub-id pub-id-type="pmid">29510028</pub-id></element-citation></ref><ref id="B59-molecules-28-04183"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
</person-group><article-title>DNA recognition by a novel bis-intercalator, potent anticancer drug XR5944</article-title><source>Curr. Top. Med. Chem.</source><year>2015</year><volume>15</volume><fpage>1385</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.2174/1568026615666150413155608</pub-id><pub-id pub-id-type="pmid">25866279</pub-id></element-citation></ref><ref id="B60-molecules-28-04183"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guttenberger</surname><given-names>N.</given-names></name>
<name><surname>Blankenfeldt</surname><given-names>W.</given-names></name>
<name><surname>Breinbauer</surname><given-names>R.</given-names></name>
</person-group><article-title>Recent developments in the isolation, biological function, biosynthesis, and synthesis of phenazine natural products</article-title><source>Bioorg. Med. Chem.</source><year>2017</year><volume>25</volume><fpage>6149</fpage><lpage>6166</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.01.002</pub-id><pub-id pub-id-type="pmid">28094222</pub-id></element-citation></ref><ref id="B61-molecules-28-04183"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heine</surname><given-names>D.</given-names></name>
<name><surname>Martin</surname><given-names>K.</given-names></name>
<name><surname>Hertweck</surname><given-names>C.</given-names></name>
</person-group><article-title>Genomics-guided discovery of endophenazines from <italic toggle="yes">Kitasatospora</italic> sp. HKI 714</article-title><source>J. Nat. Prod.</source><year>2014</year><volume>77</volume><fpage>1083</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1021/np400915p</pub-id><pub-id pub-id-type="pmid">24617951</pub-id></element-citation></ref><ref id="B62-molecules-28-04183"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blin</surname><given-names>K.</given-names></name>
<name><surname>Shaw</surname><given-names>S.</given-names></name>
<name><surname>Kloosterman</surname><given-names>A.M.</given-names></name>
<name><surname>Charlop-Powers</surname><given-names>Z.</given-names></name>
<name><surname>van Wezel</surname><given-names>G.P.</given-names></name>
<name><surname>Medema</surname><given-names>M.H.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
</person-group><article-title>antiSMASH 6.0: Improving cluster detection and comparison capabilities</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>W29</fpage><lpage>W35</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab335</pub-id><pub-id pub-id-type="pmid">33978755</pub-id></element-citation></ref><ref id="B63-molecules-28-04183"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.-M.</given-names></name>
<name><surname>Brachmann</surname><given-names>A.O.</given-names></name>
<name><surname>Westphalen</surname><given-names>M.A.</given-names></name>
<name><surname>Neubacher</surname><given-names>N.</given-names></name>
<name><surname>Tobias</surname><given-names>N.J.</given-names></name>
<name><surname>Bode</surname><given-names>H.B.</given-names></name>
</person-group><article-title>Dual phenazine gene clusters enable diversification during biosynthesis</article-title><source>Nat. Chem. Biol.</source><year>2019</year><volume>15</volume><fpage>331</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/s41589-019-0246-1</pub-id><pub-id pub-id-type="pmid">30886436</pub-id></element-citation></ref><ref id="B64-molecules-28-04183"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giddens</surname><given-names>S.R.</given-names></name>
<name><surname>Bean</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Investigations into the in vitro antimicrobial activity and mode of action of the phenazine antibiotic d-alanylgriseoluteic acid</article-title><source>Int. J. Antimicrob. Agents.</source><year>2007</year><volume>29</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2006.08.028</pub-id><pub-id pub-id-type="pmid">17189100</pub-id></element-citation></ref><ref id="B65-molecules-28-04183"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>van Wezel</surname><given-names>G.P.</given-names></name>
<name><surname>Hae Choi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Identification of novel endophenaside antibiotics produced by <italic toggle="yes">Kitasatospora</italic> sp. MBT66</article-title><source>J. Antibiot.</source><year>2015</year><volume>68</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/ja.2015.14</pub-id></element-citation></ref><ref id="B66-molecules-28-04183"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
<name><surname>Rong</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
</person-group><article-title>Diastaphenazine, a new dimeric phenazine from an endophytic <italic toggle="yes">Streptomyces diastaticus</italic> subsp</article-title><source>ardesiacus. J. Antibiot.</source><year>2015</year><volume>68</volume><fpage>210</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.124</pub-id></element-citation></ref><ref id="B67-molecules-28-04183"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rui</surname><given-names>Z.</given-names></name>
<name><surname>Ye</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Fujikawa</surname><given-names>K.</given-names></name>
<name><surname>Akerele</surname><given-names>B.</given-names></name>
<name><surname>Aung</surname><given-names>M.</given-names></name>
<name><surname>Floss</surname><given-names>H.G.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>T.W.</given-names></name>
</person-group><article-title>Insights into a divergent phenazine biosynthetic pathway governed by a plasmid-born esmeraldin gene cluster</article-title><source>Chem. Biol.</source><year>2012</year><volume>19</volume><fpage>1116</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.07.025</pub-id><pub-id pub-id-type="pmid">22999880</pub-id></element-citation></ref><ref id="B68-molecules-28-04183"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Qian</surname><given-names>G.</given-names></name>
<name><surname>Ye</surname><given-names>Y.</given-names></name>
<name><surname>Wright</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
</person-group><article-title>Heterocyclic aromatic N-Oxidation in the biosynthesis of phenazine antibiotics from <italic toggle="yes">Lysobacter antibioticus</italic></article-title><source>Org. Lett.</source><year>2016</year><volume>18</volume><fpage>2495</fpage><lpage>2498</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.6b01089</pub-id><pub-id pub-id-type="pmid">27145204</pub-id></element-citation></ref><ref id="B69-molecules-28-04183"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitova</surname><given-names>M.I.</given-names></name>
<name><surname>Lang</surname><given-names>G.</given-names></name>
<name><surname>Wiese</surname><given-names>J.</given-names></name>
<name><surname>Imhoff</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Subinhibitory concentrations of antibiotics induce phenazine production in a marine <italic toggle="yes">Streptomyces</italic> sp</article-title><source>J. Nat. Prod.</source><year>2008</year><volume>71</volume><fpage>824</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1021/np800032a</pub-id><pub-id pub-id-type="pmid">18396903</pub-id></element-citation></ref><ref id="B70-molecules-28-04183"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gomez-Escribano</surname><given-names>J.P.</given-names></name>
<name><surname>Bibb</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Heterologous expression of natural product biosynthetic gene clusters in Streptomyces coelicolor: From genome mining to manipulation of biosynthetic pathways</article-title><source>J. Ind. Microbiol. Technol.</source><year>2014</year><volume>41</volume><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1007/s10295-013-1348-5</pub-id></element-citation></ref><ref id="B71-molecules-28-04183"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saleh</surname><given-names>O.</given-names></name>
<name><surname>Flinspach</surname><given-names>K.</given-names></name>
<name><surname>Westrich</surname><given-names>L.</given-names></name>
<name><surname>Kulik</surname><given-names>A.</given-names></name>
<name><surname>Gust</surname><given-names>B.</given-names></name>
<name><surname>Fiedler</surname><given-names>H.-P.</given-names></name>
<name><surname>Heide</surname><given-names>L.</given-names></name>
</person-group><article-title>Mutational analysis of a phenazine biosynthetic gene cluster in <italic toggle="yes">Streptomyces anulatus</italic> 9663</article-title><source>Beilstein J. Org. Chem.</source><year>2012</year><volume>8</volume><fpage>501</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.3762/bjoc.8.57</pub-id><pub-id pub-id-type="pmid">22509222</pub-id></element-citation></ref><ref id="B72-molecules-28-04183"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saleh</surname><given-names>O.</given-names></name>
<name><surname>Bonitz</surname><given-names>T.</given-names></name>
<name><surname>Flinspach</surname><given-names>K.</given-names></name>
<name><surname>Kulik</surname><given-names>A.</given-names></name>
<name><surname>Burkard</surname><given-names>N.</given-names></name>
<name><surname>M&#x000fc;hlenweg</surname><given-names>A.</given-names></name>
<name><surname>Vente</surname><given-names>A.</given-names></name>
<name><surname>Polnick</surname><given-names>S.</given-names></name>
<name><surname>L&#x000e4;mmerhofer</surname><given-names>M.</given-names></name>
<name><surname>Gust</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Activation of a silent phenazine biosynthetic gene cluster reveals a novel natural product and a new resistance mechanism against phenazines</article-title><source>Med. Chem. Commun.</source><year>2012</year><volume>3</volume><fpage>1009</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1039/c2md20045g</pub-id></element-citation></ref><ref id="B73-molecules-28-04183"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lechartier</surname><given-names>B.</given-names></name>
<name><surname>Cole</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Mode of action of clofazimine and combination therapy with benzothiazinones against <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>4457</fpage><lpage>4463</lpage><pub-id pub-id-type="doi">10.1128/AAC.00395-15</pub-id><?supplied-pmid 25987624?><pub-id pub-id-type="pmid">25987624</pub-id></element-citation></ref><ref id="B74-molecules-28-04183"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant Tuberculosis</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><fpage>8409</fpage><lpage>8417</lpage><pub-id pub-id-type="doi">10.1021/jm300828h</pub-id><pub-id pub-id-type="pmid">22931472</pub-id></element-citation></ref><ref id="B75-molecules-28-04183"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<name><surname>Fu</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>D.</given-names></name>
<name><surname>Cooper</surname><given-names>C.B.</given-names></name>
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Synthesis and biological evaluation of novel 2-Methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>4380</fpage><lpage>4394</lpage><pub-id pub-id-type="doi">10.3390/molecules19044380</pub-id><pub-id pub-id-type="pmid">24722591</pub-id></element-citation></ref><ref id="B76-molecules-28-04183"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>C.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant Tuberculosis</article-title><source>Molecules</source><year>2012</year><volume>17</volume><fpage>4545</fpage><lpage>4559</lpage><pub-id pub-id-type="doi">10.3390/molecules17044545</pub-id><pub-id pub-id-type="pmid">22510605</pub-id></element-citation></ref><ref id="B77-molecules-28-04183"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coelho</surname><given-names>T.S.</given-names></name>
<name><surname>Silva</surname><given-names>R.S.F.</given-names></name>
<name><surname>Pinto</surname><given-names>A.V.</given-names></name>
<name><surname>Pinto</surname><given-names>M.C.F.R.</given-names></name>
<name><surname>Scaini</surname><given-names>C.J.</given-names></name>
<name><surname>Moura</surname><given-names>K.C.G.</given-names></name>
<name><surname>Almeida da Silva</surname><given-names>P.</given-names></name>
</person-group><article-title>Activity of &#x003b2;-lapachone derivatives against rifampicin-susceptible and -resistant strains of Mycobacterium tuberculosis</article-title><source>Tuberculosis</source><year>2010</year><volume>90</volume><fpage>293</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2010.06.001</pub-id><pub-id pub-id-type="pmid">20663716</pub-id></element-citation></ref><ref id="B78-molecules-28-04183"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borrero</surname><given-names>N.V.</given-names></name>
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Perez</surname><given-names>C.</given-names></name>
<name><surname>Duong</surname><given-names>B.Q.</given-names></name>
<name><surname>Rocca</surname><given-names>J.R.</given-names></name>
<name><surname>Jin</surname><given-names>S.</given-names></name>
<name><surname>Huigens Iii</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Staphylococcus epidermidis</italic></article-title><source>Org. Biomol. Chem.</source><year>2014</year><volume>12</volume><fpage>881</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1039/C3OB42416B</pub-id><pub-id pub-id-type="pmid">24389824</pub-id></element-citation></ref><ref id="B79-molecules-28-04183"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garrison</surname><given-names>A.T.</given-names></name>
<name><surname>Abouelhassan</surname><given-names>Y.</given-names></name>
<name><surname>Norwood</surname><given-names>V.M.I.V.</given-names></name>
<name><surname>Kallifidas</surname><given-names>D.</given-names></name>
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.T.</given-names></name>
<name><surname>Rolfe</surname><given-names>M.</given-names></name>
<name><surname>Burch</surname><given-names>G.M.</given-names></name>
<name><surname>Jin</surname><given-names>S.</given-names></name>
<name><surname>Luesch</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Structure&#x02013;activity relationships of a diverse class of halogenated phenazines that targets persistent, antibiotic-tolerant bacterial biofilms and <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>3808</fpage><lpage>3825</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b02004</pub-id><pub-id pub-id-type="pmid">27018907</pub-id></element-citation></ref><ref id="B80-molecules-28-04183"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garrison</surname><given-names>A.T.</given-names></name>
<name><surname>Abouelhassan</surname><given-names>Y.</given-names></name>
<name><surname>Kallifidas</surname><given-names>D.</given-names></name>
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Ukhanova</surname><given-names>M.</given-names></name>
<name><surname>Mai</surname><given-names>V.</given-names></name>
<name><surname>Jin</surname><given-names>S.</given-names></name>
<name><surname>Luesch</surname><given-names>H.</given-names></name>
<name><surname>Huigens</surname><given-names>R.W.</given-names><suffix>3rd</suffix></name>
</person-group><article-title>Halogenated phenazines that potently eradicate biofilms, MRSA persister cells in non-biofilm cultures, and <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2015</year><volume>54</volume><fpage>14819</fpage><lpage>14823</lpage><pub-id pub-id-type="doi">10.1002/anie.201508155</pub-id><pub-id pub-id-type="pmid">26480852</pub-id></element-citation></ref><ref id="B81-molecules-28-04183"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huigens</surname><given-names>R.W.</given-names><suffix>3rd</suffix></name>
<name><surname>Abouelhassan</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><article-title>Phenazine antibiotic-inspired discovery of bacterial biofilm-eradicating agents</article-title><source>Chembiochem</source><year>2019</year><volume>20</volume><fpage>2885</fpage><lpage>2902</lpage><pub-id pub-id-type="doi">10.1002/cbic.201900116</pub-id><?supplied-pmid 30811834?><pub-id pub-id-type="pmid">30811834</pub-id></element-citation></ref><ref id="B82-molecules-28-04183"><label>82.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Reusch</surname><given-names>W.</given-names></name>
</person-group><article-title>Textbook of Organic Chemistry</article-title><comment>Available online: <ext-link xlink:href="https://chem.libretexts.org/Bookshelves/Organic_Chemistry/Supplemental_Modules_(Organic_Chemistry)/Lipids/Properties_and_Classification_of_Lipids/Terpenes" ext-link-type="uri">https://chem.libretexts.org/Bookshelves/Organic_Chemistry/Supplemental_Modules_(Organic_Chemistry)/Lipids/Properties_and_Classification_of_Lipids/Terpenes</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-06">(accessed on 6 January 2023)</date-in-citation></element-citation></ref><ref id="B83-molecules-28-04183"><label>83.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Soderberg</surname><given-names>T.</given-names></name>
<name><surname>Reusch</surname><given-names>W.</given-names></name>
<name><surname>Farmer</surname><given-names>S.</given-names></name>
<name><surname>Kennepohl</surname><given-names>D.</given-names></name>
</person-group><article-title>Terpenoids</article-title><comment>Available online: <ext-link xlink:href="https://chem.libretexts.org/Courses/Athabasca_University/Chemistry_360%3A_Organic_Chemistry_II/Chapter_27%3A_Biomolecules_-_Lipids/27.05_Terpenoids" ext-link-type="uri">https://chem.libretexts.org/Courses/Athabasca_University/Chemistry_360%3A_Organic_Chemistry_II/Chapter_27%3A_Biomolecules_-_Lipids/27.05_Terpenoids</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-01-06">(accessed on 6 January 2023)</date-in-citation></element-citation></ref><ref id="B84-molecules-28-04183"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Sun</surname><given-names>P.</given-names></name>
</person-group><article-title>Isolation and identification of pentalenolactone analogs from <italic toggle="yes">Streptomyces</italic> sp. NRRL S-4</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>7377</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26237377</pub-id><?supplied-pmid 34885958?><pub-id pub-id-type="pmid">34885958</pub-id></element-citation></ref><ref id="B85-molecules-28-04183"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Adpressa</surname><given-names>D.A.</given-names></name>
<name><surname>Rudolf</surname><given-names>J.D.</given-names></name>
<name><surname>Loesgen</surname><given-names>S.</given-names></name>
</person-group><article-title>Discovery and biosynthesis of a structurally dynamic antibacterial diterpenoid</article-title><source>Angew Chem. Int. Ed. Engl.</source><year>2021</year><volume>60</volume><fpage>14163</fpage><lpage>14170</lpage><pub-id pub-id-type="doi">10.1002/anie.202102453</pub-id><?supplied-pmid 33780586?><pub-id pub-id-type="pmid">33780586</pub-id></element-citation></ref><ref id="B86-molecules-28-04183"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Footy</surname><given-names>K.O.</given-names></name>
<name><surname>Alarif</surname><given-names>W.M.</given-names></name>
<name><surname>Asiri</surname><given-names>F.</given-names></name>
<name><surname>Aly</surname><given-names>M.M.</given-names></name>
<name><surname>Ayyad</surname><given-names>S.-E.N.</given-names></name>
</person-group><article-title>Rare pyrane-based cembranoids from the Red Sea soft coral Sarcophyton trocheliophorum as potential antimicrobial&#x02013;antitumor agents</article-title><source>Med. Chem. Res.</source><year>2015</year><volume>24</volume><fpage>505</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1007/s00044-014-1147-1</pub-id></element-citation></ref><ref id="B87-molecules-28-04183"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Subramani</surname><given-names>R.</given-names></name>
<name><surname>Aalbersberg</surname><given-names>W.</given-names></name>
</person-group><article-title>Three bioactive sesquiterpene quinones from the Fijian marine sponge of the genus <italic toggle="yes">Hippospongia</italic></article-title><source>Nat. Prod. Res.</source><year>2013</year><volume>27</volume><fpage>1488</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1080/14786419.2012.722086</pub-id><?supplied-pmid 22963320?><pub-id pub-id-type="pmid">22963320</pub-id></element-citation></ref><ref id="B88-molecules-28-04183"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kudo</surname><given-names>F.</given-names></name>
<name><surname>Matsuura</surname><given-names>Y.</given-names></name>
<name><surname>Hayashi</surname><given-names>T.</given-names></name>
<name><surname>Fukushima</surname><given-names>M.</given-names></name>
<name><surname>Eguchi</surname><given-names>T.</given-names></name>
</person-group><article-title>Genome mining of the sordarin biosynthetic gene cluster from <italic toggle="yes">Sordaria araneosa</italic> Cain ATCC 36386: Characterization of cycloaraneosene synthase and GDP-6-deoxyaltrose transferase</article-title><source>J. Antibiot.</source><year>2016</year><volume>69</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/ja.2016.40</pub-id><?supplied-pmid 27072286?><pub-id pub-id-type="pmid">27072286</pub-id></element-citation></ref><ref id="B89-molecules-28-04183"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanadate</surname><given-names>T.</given-names></name>
<name><surname>Tomishima</surname><given-names>M.</given-names></name>
<name><surname>Shiraishi</surname><given-names>N.</given-names></name>
<name><surname>Tanabe</surname><given-names>D.</given-names></name>
<name><surname>Morikawa</surname><given-names>H.</given-names></name>
<name><surname>Barrett</surname><given-names>D.</given-names></name>
<name><surname>Matsumoto</surname><given-names>S.</given-names></name>
<name><surname>Ohtomo</surname><given-names>K.</given-names></name>
<name><surname>Maki</surname><given-names>K.</given-names></name>
</person-group><article-title>FR290581, a novel sordarin derivative: Synthesis and antifungal activity</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2009</year><volume>19</volume><fpage>1465</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2009.01.051</pub-id><pub-id pub-id-type="pmid">19196509</pub-id></element-citation></ref><ref id="B90-molecules-28-04183"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bueno</surname><given-names>J.M.</given-names></name>
<name><surname>Chicharro</surname><given-names>J.</given-names></name>
<name><surname>Fiandor</surname><given-names>J.M.</given-names></name>
<name><surname>G&#x000f3;mez de las Heras</surname><given-names>F.</given-names></name>
<name><surname>Huss</surname><given-names>S.</given-names></name>
</person-group><article-title>Antifungal sordarins. Part 4: Synthesis and structure&#x02013;activity relationships of 3&#x02032;,4&#x02032;-fused alkyl-tetrahydrofuran derivatives</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2002</year><volume>12</volume><fpage>1697</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(02)00293-7</pub-id><pub-id pub-id-type="pmid">12067540</pub-id></element-citation></ref><ref id="B91-molecules-28-04183"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bommineni</surname><given-names>G.R.</given-names></name>
<name><surname>Kapilashrami</surname><given-names>K.</given-names></name>
<name><surname>Cummings</surname><given-names>J.E.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Knudson</surname><given-names>S.E.</given-names></name>
<name><surname>Gu</surname><given-names>C.</given-names></name>
<name><surname>Walker</surname><given-names>S.G.</given-names></name>
<name><surname>Slayden</surname><given-names>R.A.</given-names></name>
<name><surname>Tonge</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Thiolactomycin-based inhibitors of bacterial &#x003b2;-ketoacyl-ACP synthases with in vivo activity</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>5377</fpage><lpage>5390</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00236</pub-id><pub-id pub-id-type="pmid">27187871</pub-id></element-citation></ref><ref id="B92-molecules-28-04183"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kondratyuk</surname><given-names>T.P.</given-names></name>
<name><surname>Park</surname><given-names>E.-J.</given-names></name>
<name><surname>Yu</surname><given-names>R.</given-names></name>
<name><surname>Van Breemen</surname><given-names>R.B.</given-names></name>
<name><surname>Asolkar</surname><given-names>R.N.</given-names></name>
<name><surname>Murphy</surname><given-names>B.T.</given-names></name>
<name><surname>Fenical</surname><given-names>W.</given-names></name>
<name><surname>Pezzuto</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Novel marine phenazines as potential cancer chemopreventive and anti-inflammatory agents</article-title><source>Mar. Drugs.</source><year>2012</year><volume>10</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.3390/md10020451</pub-id><pub-id pub-id-type="pmid">22412812</pub-id></element-citation></ref><ref id="B93-molecules-28-04183"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munita</surname><given-names>J.M.</given-names></name>
<name><surname>Arias</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Mechanisms of antibiotic resistance</article-title><source>Microbiol. Spectr.</source><year>2016</year><volume>4</volume><fpage>481</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.VMBF-0016-2015</pub-id></element-citation></ref><ref id="B94-molecules-28-04183"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bush</surname><given-names>K.</given-names></name>
<name><surname>Bradford</surname><given-names>P.A.</given-names></name>
</person-group><article-title>&#x003b2;-Lactams and &#x003b2;-lactamase inhibitors: An overview</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a025247</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a025247</pub-id><pub-id pub-id-type="pmid">27329032</pub-id></element-citation></ref><ref id="B95-molecules-28-04183"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Worthington</surname><given-names>R.J.</given-names></name>
<name><surname>Melander</surname><given-names>C.</given-names></name>
</person-group><article-title>Overcoming resistance to &#x003b2;-lactam antibiotics</article-title><source>J. Org. Chem.</source><year>2013</year><volume>78</volume><fpage>4207</fpage><lpage>4213</lpage><pub-id pub-id-type="doi">10.1021/jo400236f</pub-id><pub-id pub-id-type="pmid">23530949</pub-id></element-citation></ref><ref id="B96-molecules-28-04183"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dinos</surname><given-names>G.P.</given-names></name>
</person-group><article-title>The macrolide antibiotic renaissance</article-title><source>Br. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>2967</fpage><lpage>2983</lpage><pub-id pub-id-type="doi">10.1111/bph.13936</pub-id><?supplied-pmid 28664582?><pub-id pub-id-type="pmid">28664582</pub-id></element-citation></ref><ref id="B97-molecules-28-04183"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>E.A.</given-names></name>
<name><surname>Korzheva</surname><given-names>N.</given-names></name>
<name><surname>Mustaev</surname><given-names>A.</given-names></name>
<name><surname>Murakami</surname><given-names>K.</given-names></name>
<name><surname>Nair</surname><given-names>S.</given-names></name>
<name><surname>Goldfarb</surname><given-names>A.</given-names></name>
<name><surname>Darst</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Structural mechanism for rifampicin inhibition of bacterial RNA polymerase</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>901</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00286-0</pub-id><?supplied-pmid 11290327?><pub-id pub-id-type="pmid">11290327</pub-id></element-citation></ref><ref id="B98-molecules-28-04183"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Resistance to rifampicin: A review</article-title><source>J. Antibiot.</source><year>2014</year><volume>67</volume><fpage>625</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1038/ja.2014.107</pub-id><?supplied-pmid 25118103?><pub-id pub-id-type="pmid">25118103</pub-id></element-citation></ref><ref id="B99-molecules-28-04183"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Javid</surname><given-names>B.</given-names></name>
<name><surname>Sorrentino</surname><given-names>F.</given-names></name>
<name><surname>Toosky</surname><given-names>M.</given-names></name>
<name><surname>Zheng</surname><given-names>W.</given-names></name>
<name><surname>Pinkham</surname><given-names>J.T.</given-names></name>
<name><surname>Jain</surname><given-names>N.</given-names></name>
<name><surname>Pan</surname><given-names>M.</given-names></name>
<name><surname>Deighan</surname><given-names>P.</given-names></name>
<name><surname>Rubin</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Mycobacterial mistranslation is necessary and sufficient for rifampicin phenotypic resistance</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>1132</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317580111</pub-id><pub-id pub-id-type="pmid">24395793</pub-id></element-citation></ref><ref id="B100-molecules-28-04183"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bialvaei</surname><given-names>A.Z.</given-names></name>
<name><surname>Samadi Kafil</surname><given-names>H.</given-names></name>
</person-group><article-title>Colistin, mechanisms and prevalence of resistance</article-title><source>Curr. Med. Res. Opin.</source><year>2015</year><volume>31</volume><fpage>707</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1185/03007995.2015.1018989</pub-id><pub-id pub-id-type="pmid">25697677</pub-id></element-citation></ref><ref id="B101-molecules-28-04183"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hutchings</surname><given-names>M.I.</given-names></name>
<name><surname>Truman</surname><given-names>A.W.</given-names></name>
<name><surname>Wilkinson</surname><given-names>B.</given-names></name>
</person-group><article-title>Antibiotics: Past, present and future</article-title><source>Curr. Opin. Microbiol.</source><year>2019</year><volume>51</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2019.10.008</pub-id><pub-id pub-id-type="pmid">31733401</pub-id></element-citation></ref><ref id="B102-molecules-28-04183"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>G.D.</given-names></name>
<name><surname>Denning</surname><given-names>D.W.</given-names></name>
<name><surname>Gow</surname><given-names>N.A.R.</given-names></name>
<name><surname>Levitz</surname><given-names>S.M.</given-names></name>
<name><surname>Netea</surname><given-names>M.G.</given-names></name>
<name><surname>White</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Hidden killers: Human fungal infections</article-title><source>Sci. Transl. Med.</source><year>2012</year><volume>4</volume><fpage>165rv13</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3004404</pub-id></element-citation></ref><ref id="B103-molecules-28-04183"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoenigl</surname><given-names>M.</given-names></name>
<name><surname>Seidel</surname><given-names>D.</given-names></name>
<name><surname>Sprute</surname><given-names>R.</given-names></name>
<name><surname>Cunha</surname><given-names>C.</given-names></name>
<name><surname>Oliverio</surname><given-names>M.</given-names></name>
<name><surname>Goldman</surname><given-names>G.H.</given-names></name>
<name><surname>Ibrahim</surname><given-names>A.S.</given-names></name>
<name><surname>Carvalho</surname><given-names>A.</given-names></name>
</person-group><article-title>COVID-19-associated fungal infections</article-title><source>Nat. Microbiol.</source><year>2022</year><volume>7</volume><fpage>1127</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01172-2</pub-id><pub-id pub-id-type="pmid">35918423</pub-id></element-citation></ref><ref id="B104-molecules-28-04183"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Armstrong-James</surname><given-names>D.</given-names></name>
<name><surname>Meintjes</surname><given-names>G.</given-names></name>
<name><surname>Brown</surname><given-names>G.D.</given-names></name>
</person-group><article-title>A neglected epidemic: Fungal infections in HIV/AIDS</article-title><source>Trends Microbiol.</source><year>2014</year><volume>22</volume><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2014.01.001</pub-id><pub-id pub-id-type="pmid">24530175</pub-id></element-citation></ref><ref id="B105-molecules-28-04183"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenks</surname><given-names>J.D.</given-names></name>
<name><surname>Cornely</surname><given-names>O.A.</given-names></name>
<name><surname>Chen</surname><given-names>S.C.</given-names></name>
<name><surname>Thompson</surname><given-names>G.R.</given-names><suffix>3rd</suffix></name>
<name><surname>Hoenigl</surname><given-names>M.</given-names></name>
</person-group><article-title>Breakthrough invasive fungal infections: Who is at risk?</article-title><source>Mycoses</source><year>2020</year><volume>63</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1111/myc.13148</pub-id><pub-id pub-id-type="pmid">32744334</pub-id></element-citation></ref><ref id="B106-molecules-28-04183"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Francois</surname><given-names>I.E.</given-names></name>
<name><surname>Aerts</surname><given-names>A.M.</given-names></name>
<name><surname>Cammue</surname><given-names>B.P.</given-names></name>
<name><surname>Thevissen</surname><given-names>K.</given-names></name>
</person-group><article-title>Currently used antimycotics: Spectrum, mode of action and resistance occurrence</article-title><source>Curr. Drug Targets</source><year>2005</year><volume>6</volume><fpage>895</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.2174/138945005774912744</pub-id><?supplied-pmid 16375673?><pub-id pub-id-type="pmid">16375673</pub-id></element-citation></ref><ref id="B107-molecules-28-04183"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Puumala</surname><given-names>E.</given-names></name>
<name><surname>Robbins</surname><given-names>N.</given-names></name>
<name><surname>Cowen</surname><given-names>L.E.</given-names></name>
</person-group><article-title>Antifungal drug resistance: Molecular mechanisms in <italic toggle="yes">Candida albicans</italic> and beyond</article-title><source>Chem. Rev.</source><year>2021</year><volume>121</volume><fpage>3390</fpage><lpage>3411</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c00199</pub-id><pub-id pub-id-type="pmid">32441527</pub-id></element-citation></ref><ref id="B108-molecules-28-04183"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pappas</surname><given-names>P.G.</given-names></name>
<name><surname>Kauffman</surname><given-names>C.A.</given-names></name>
<name><surname>Andes</surname><given-names>D.R.</given-names></name>
<name><surname>Clancy</surname><given-names>C.J.</given-names></name>
<name><surname>Marr</surname><given-names>K.A.</given-names></name>
<name><surname>Ostrosky-Zeichner</surname><given-names>L.</given-names></name>
<name><surname>Reboli</surname><given-names>A.C.</given-names></name>
<name><surname>Schuster</surname><given-names>M.G.</given-names></name>
<name><surname>Vazquez</surname><given-names>J.A.</given-names></name>
<name><surname>Walsh</surname><given-names>T.J.</given-names></name>
<etal/>
</person-group><article-title>Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>62</volume><fpage>e1</fpage><lpage>e50</lpage><pub-id pub-id-type="doi">10.1093/cid/civ933</pub-id><?supplied-pmid 26679628?><pub-id pub-id-type="pmid">26679628</pub-id></element-citation></ref><ref id="B109-molecules-28-04183"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patterson</surname><given-names>T.F.</given-names></name>
<name><surname>Thompson</surname><given-names>G.R.</given-names><suffix>III</suffix></name>
<name><surname>Denning</surname><given-names>D.W.</given-names></name>
<name><surname>Fishman</surname><given-names>J.A.</given-names></name>
<name><surname>Hadley</surname><given-names>S.</given-names></name>
<name><surname>Herbrecht</surname><given-names>R.</given-names></name>
<name><surname>Kontoyiannis</surname><given-names>D.P.</given-names></name>
<name><surname>Marr</surname><given-names>K.A.</given-names></name>
<name><surname>Morrison</surname><given-names>V.A.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.H.</given-names></name>
<etal/>
</person-group><article-title>Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>e1</fpage><lpage>e60</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw326</pub-id><pub-id pub-id-type="pmid">27365388</pub-id></element-citation></ref><ref id="B110-molecules-28-04183"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghannoum</surname><given-names>M.A.</given-names></name>
<name><surname>Rice</surname><given-names>L.B.</given-names></name>
</person-group><article-title>Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance</article-title><source>Clin. Microbiol. Rev.</source><year>1999</year><volume>12</volume><fpage>501</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1128/CMR.12.4.501</pub-id><?supplied-pmid 10515900?><pub-id pub-id-type="pmid">10515900</pub-id></element-citation></ref><ref id="B111-molecules-28-04183"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caffrey</surname><given-names>P.</given-names></name>
<name><surname>Lynch</surname><given-names>S.</given-names></name>
<name><surname>Flood</surname><given-names>E.</given-names></name>
<name><surname>Finnan</surname><given-names>S.</given-names></name>
<name><surname>Oliynyk</surname><given-names>M.</given-names></name>
</person-group><article-title>Amphotericin biosynthesis in <italic toggle="yes">Streptomyces nodosus</italic>: Deductions from analysis of polyketide synthase and late genes</article-title><source>Chem. Biol.</source><year>2001</year><volume>8</volume><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00046-1</pub-id><?supplied-pmid 11451671?><pub-id pub-id-type="pmid">11451671</pub-id></element-citation></ref><ref id="B112-molecules-28-04183"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carolus</surname><given-names>H.</given-names></name>
<name><surname>Pierson</surname><given-names>S.</given-names></name>
<name><surname>Lagrou</surname><given-names>K.</given-names></name>
<name><surname>Van Dijck</surname><given-names>P.</given-names></name>
</person-group><article-title>Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance</article-title><source>J. Fungi</source><year>2020</year><volume>6</volume><elocation-id>321</elocation-id><pub-id pub-id-type="doi">10.3390/jof6040321</pub-id></element-citation></ref><ref id="B113-molecules-28-04183"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Denning</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Echinocandin antifungal drugs</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14472-8</pub-id><pub-id pub-id-type="pmid">14550704</pub-id></element-citation></ref><ref id="B114-molecules-28-04183"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>H&#x000fc;ttel</surname><given-names>W.</given-names></name>
</person-group><article-title>Echinocandins: Structural diversity, biosynthesis, and development of antimycotics</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2021</year><volume>105</volume><fpage>55</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s00253-020-11022-y</pub-id><pub-id pub-id-type="pmid">33270153</pub-id></element-citation></ref><ref id="B115-molecules-28-04183"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ostrosky-Zeichner</surname><given-names>L.</given-names></name>
<name><surname>Casadevall</surname><given-names>A.</given-names></name>
<name><surname>Galgiani</surname><given-names>J.N.</given-names></name>
<name><surname>Odds</surname><given-names>F.C.</given-names></name>
<name><surname>Rex</surname><given-names>J.H.</given-names></name>
</person-group><article-title>An insight into the antifungal pipeline: Selected new molecules and beyond</article-title><source>Nat. Rev. Drug Discov.</source><year>2010</year><volume>9</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1038/nrd3074</pub-id><pub-id pub-id-type="pmid">20725094</pub-id></element-citation></ref><ref id="B116-molecules-28-04183"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shao</surname><given-names>Y.</given-names></name>
<name><surname>Molestak</surname><given-names>E.</given-names></name>
<name><surname>Su</surname><given-names>W.</given-names></name>
<name><surname>Stankevi&#x0010d;</surname><given-names>M.</given-names></name>
<name><surname>Tch&#x000f3;rzewski</surname><given-names>M.</given-names></name>
</person-group><article-title>Sordarin- an anti-fungal antibiotic with a unique modus operandi</article-title><source>Br. J. Pharmacol.</source><year>2022</year><volume>179</volume><fpage>1125</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1111/bph.15724</pub-id><?supplied-pmid 34767248?><pub-id pub-id-type="pmid">34767248</pub-id></element-citation></ref><ref id="B117-molecules-28-04183"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Zaleta-Rivera</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Huffman</surname><given-names>J.</given-names></name>
<name><surname>Millet</surname><given-names>J.C.</given-names></name>
<name><surname>Harris</surname><given-names>S.D.</given-names></name>
<name><surname>Yuen</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>X.-C.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
</person-group><article-title>Structure and biosynthesis of heat-stable antifungal factor (HSAF), a broad-spectrum antimycotic with a novel mode of action</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1128/AAC.00931-06</pub-id><?supplied-pmid 17074795?><pub-id pub-id-type="pmid">17074795</pub-id></element-citation></ref><ref id="B118-molecules-28-04183"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
</person-group><article-title>Indole-induced reversion of intrinsic multiantibiotic resistance in <italic toggle="yes">Lysobacter enzymogenes</italic></article-title><source>Appl. Environ. Microbiol.</source><year>2017</year><volume>83</volume><fpage>e00995-17</fpage><pub-id pub-id-type="doi">10.1128/AEM.00995-17</pub-id><?supplied-pmid 28625984?><pub-id pub-id-type="pmid">28625984</pub-id></element-citation></ref><ref id="B119-molecules-28-04183"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
</person-group><article-title>HSAF-induced antifungal effects in <italic toggle="yes">Candida albicans</italic> through ROS-mediated apoptosis</article-title><source>RSC Adv.</source><year>2016</year><volume>6</volume><fpage>30895</fpage><lpage>30904</lpage><pub-id pub-id-type="doi">10.1039/C5RA26092B</pub-id><pub-id pub-id-type="pmid">27594989</pub-id></element-citation></ref><ref id="B120-molecules-28-04183"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherlach</surname><given-names>K.</given-names></name>
<name><surname>Hertweck</surname><given-names>C.</given-names></name>
</person-group><article-title>Mining and unearthing hidden biosynthetic potential</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>3864</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24133-5</pub-id><pub-id pub-id-type="pmid">34162873</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Table</title><fig position="float" id="molecules-28-04183-f001"><label>Figure 1</label><caption><p>Three generations of macrolide antibiotics developed from erythromycin. The natural product polyketide macrolide antibiotic erythromycin (<bold>1</bold>) is produced by <italic toggle="yes">Saccharopolyspora erythraea</italic>. Clarithromycin (<bold>2</bold>) and azithromycin (<bold>3</bold>) are semisynthetic derivatives with enhanced activity and are active against erythromycin-resistant <italic toggle="yes">Streptococcus pneumoniae</italic>. These three examples demonstrate a widely accepted approach in drug discovery and development, that is to modify an already known drug to develop new drugs, which has been practiced for many years by pharmaceutical companies and researchers.</p></caption><graphic xlink:href="molecules-28-04183-g001" position="float"/></fig><fig position="float" id="molecules-28-04183-sch001"><object-id pub-id-type="pii">molecules-28-04183-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Roadmap of genome-mining-guided novel natural product discovery. The typical steps of genome mining for novel antibiotics are as follows. (1) Natural compound producers are collected from various sources. (2) The genomes of natural compound producers are sequenced. (3) The sequenced genomes are analyzed for biosynthesis gene clusters (BGCs). (4) Computational algorithms are used to predict enzymatic modules and post-assembly tailoring enzymes. (5) The producers of interest (such as bacteria and fungi) are often fermented to express the target compounds. (6) Chromatography-based separation is deployed to obtain purified compounds. (7) The target compounds are characterized through analytical methods such as HPLC and MS. (8) The chemical structures are elucidated by NMR or single crystal diffraction. (9) The biological activities of the compounds are investigated. These steps of excavating a bacterial genome for BGCs leading to the discovery of a novel antibiotic were exemplified by ECO-0501, a glycosidic polyketide.</p></caption><graphic xlink:href="molecules-28-04183-sch001" position="float"/></fig><fig position="float" id="molecules-28-04183-f002"><label>Figure 2</label><caption><p>Representative antibiotics of the polyketide class. Red marks components derived from 3-amino-5-hydroxybenzoic acid (AHBA), the starter unit in neoansamycins (<bold>11</bold>, <bold>12</bold>). HSAF (<bold>17</bold>) is a heat-stable antifungal factor, a drug candidate with exemplary bioactivities and a novel antifungal mode of action.</p></caption><graphic xlink:href="molecules-28-04183-g002" position="float"/></fig><fig position="float" id="molecules-28-04183-f003"><label>Figure 3</label><caption><p>Representative antibiotics of the nonribosomal peptide class. The &#x003b2;-lactam ring of penicillin (<bold>18</bold>) is marked in red. The amino acids at A3, A7, and A10 positions of the cyclic polypeptide of Colistin (<bold>31</bold>), also known as polymyxin E, are replaced to generate macolacin (<bold>30</bold>). Green colored structures are the monomers of di-alboflavusins (<bold>38</bold>, <bold>39</bold>).</p></caption><graphic xlink:href="molecules-28-04183-g003" position="float"/></fig><fig position="float" id="molecules-28-04183-f004"><label>Figure 4</label><caption><p>Representative antibiotics of ribosomally synthesized and post-translationally modified peptides. Lanthipeptides are displayed in amino acid sequences instead of chemical structures to highlight the thioether cross-linkages.</p></caption><graphic xlink:href="molecules-28-04183-g004a" position="float"/><graphic xlink:href="molecules-28-04183-g004b" position="float"/></fig><fig position="float" id="molecules-28-04183-f005"><label>Figure 5</label><caption><p>Representative compounds of the phenazine class. Pink marks the phenazine core structures in <bold>49</bold>, <bold>50</bold>, <bold>65</bold> and <bold>66</bold>. Blue represents amino acid derived modification to <bold>77</bold> and <bold>79</bold>. Phenazine-1-carboxylic acid (PCA, <bold>49</bold>), also known as tubermycin B, has activity against <italic toggle="yes">M. tuberculosis</italic>. It is also a widely recognized natural fungicide in China that is effective and safe for the environment. Clofazimine (<bold>80</bold>) has been applied clinically to treat leprosy and multidrug-resistant <italic toggle="yes">M. tuberculosis.</italic> Endophenazine E (<bold>79</bold>) does not have an antibiotic effect, which could result from the heterologous host&#x02019;s defense mechanism.</p></caption><graphic xlink:href="molecules-28-04183-g005" position="float"/></fig><fig position="float" id="molecules-28-04183-f006"><label>Figure 6</label><caption><p>Representative compounds of the terpene/terpenoid class. Sordarin (<bold>94</bold>) is a glycoside antifungal agent that targets elongation factor II and halts protein synthesis. Semi-synthetic analogs FR290581 (<bold>95</bold>) and GR193663 (<bold>96</bold>) with innovative structures have shown enhanced activities compared to the original sordarin.</p></caption><graphic xlink:href="molecules-28-04183-g006" position="float"/></fig><fig position="float" id="molecules-28-04183-f007"><label>Figure 7</label><caption><p>Mechanisms of antibiotic resistance by microbes. Adapted from the BioRender template &#x0201c;Antibiotic Resistance Mechanisms&#x0201d; (2022). Retrieved from <uri xlink:href="https://app.biorender.com/biorender-templates">https://app.biorender.com/biorender-templates</uri> (accessed on 20 December 2022).</p></caption><graphic xlink:href="molecules-28-04183-g007" position="float"/></fig><fig position="float" id="molecules-28-04183-f008"><label>Figure 8</label><caption><p>Clinical antibiotics and molecular targets of bacteria. The antibiotic examples are adapted from &#x0201c;Antibiotics: past, present and future&#x0201d; [<xref rid="B102-molecules-28-04183" ref-type="bibr">102</xref>]. Figure recreated using the BioRender template &#x0201c;Antimicrobial Therapy Strategies&#x0201d; (2022). Retrieved from <uri xlink:href="https://app.biorender.com/biorender-templates">https://app.biorender.com/biorender-templates</uri> (accessed on 30 November 2022). PABA: para-amino-benzoic acid; DHF: dihydrofolic acid; THF: tetrahydrofolate. * Natural-product-inspired synthetic antibiotics. <sup>#</sup> Semi-synthetic derivatives of natural product antibiotics. <sup>&#x02020;</sup> Synthetic antibiotics, not from natural sources, but compounds from these classes are found in nature.</p></caption><graphic xlink:href="molecules-28-04183-g008" position="float"/></fig><fig position="float" id="molecules-28-04183-f009"><label>Figure 9</label><caption><p>Molecular targets of clinical antifungal agents and promising drug leads. Adapted from the BioRender template &#x0201c;Sites of Action of Antifungals&#x0201d; (2022). Retrieved from <uri xlink:href="https://app.biorender.com/biorender-templates">https://app.biorender.com/biorender-templates</uri> (accessed on 5 December 2022). * Natural-product-inspired synthetic antibiotics. <sup>&#x02020;</sup> Synthetic antibiotics, not from natural sources, but compounds from these classes are widely found in nature.</p></caption><graphic xlink:href="molecules-28-04183-g009" position="float"/></fig><table-wrap position="float" id="molecules-28-04183-t001"><object-id pub-id-type="pii">molecules-28-04183-t001_Table 1</object-id><label>Table 1</label><caption><p>Naturally sourced or nature-inspired antibiotics with activity against antimicrobial-resistant pathogens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Class</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Activity (MIC)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>ECO-0501 (4)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Amycolatopsis orientalis</italic> ATCC 43491</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (4.8 &#x003bc;M); VRE (10 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits the bacteria cell membrane and/or cell wall</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-molecules-28-04183" ref-type="bibr">9</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Anthracimycin</bold> (<bold>6</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. CNH365</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (&#x02265;0.63 &#x003bc;M); vancomycin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (&#x02265;0.63 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits RNA and/or DNA synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-molecules-28-04183" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Pyxidicyclin A</bold> (<bold>7</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Pyxidicoccus fallax</italic> An d48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> newman (36 &#x003bc;M); <italic toggle="yes">E. coli</italic> &#x00394;TolC (8 &#x003bc;M); <italic toggle="yes">C. albicans</italic> (&#x0003e;100 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Topoisomerase IV inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-molecules-28-04183" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Thiolactomycin</bold> (<bold>8</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Nocardia</italic> spp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (357 &#x003bc;M); <italic toggle="yes">Mycobacterium tuberculosis</italic> (143 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits type II fatty acid synthase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B15-molecules-28-04183" ref-type="bibr">15</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>TLM 9</bold> (<bold>9</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK/NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Semi-synthetic derivative of thiolactomycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (2.3 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits type II fatty acid synthase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-molecules-28-04183" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Isoindolinomycin</bold> (<bold>10</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. SoC090715LN-16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> (11.6 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May bind to bacterial ribosomal subunits</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-molecules-28-04183" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Neoansamycin A</bold> (<bold>11</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. LZ35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> ATCC 25923 (6 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-molecules-28-04183" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Keyicin</bold> (<bold>13</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Micromonospora</italic> sp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus subtilis</italic> (9.9 &#x003bc;M); Methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> (MSSA) (2.5 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May modulate fatty acid metabolism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-molecules-28-04183" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Turbinmicin</bold> (<bold>14</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Micromonospora</italic> sp. WMMC-415</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Panresistant <italic toggle="yes">Candidas auris</italic> B11211 (0.4 &#x003bc;M); <italic toggle="yes">C. albicans</italic> (0.4 &#x003bc;M); <italic toggle="yes">C. glabrata</italic> (0.8 &#x003bc;M); <italic toggle="yes">Aspergillus fumigatus</italic> (0.4 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeting fungal-specific Sec14 of the vesicular trafficking pathway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-molecules-28-04183" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Clostrubin</bold> (<bold>15</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Clostridium beijerincki</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (0.12 &#x003bc;<sc>M</sc>); VRE111 (0.97 &#x003bc;<sc>M</sc>); <italic toggle="yes">Bacillus subtilis</italic> (0.075 &#x003bc;<sc>M)</sc>; <italic toggle="yes">Mycobacterium smegmatis</italic> (0.48 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-molecules-28-04183" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>TP-1161</bold> (<bold>21</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Norcardiopsis</italic> sp. TSF65-07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VRE 560 and VRE 569 (0.84 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-molecules-28-04183" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Brevibacillin 2V</bold> (<bold>22</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Brevibacillus laterosporus</italic> DSM 25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (1.3 &#x003bc;M); VRE (1.3 &#x003bc;M); <italic toggle="yes">Bacillus cereus</italic> ATCC14579 (1.3 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-molecules-28-04183" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Medipeptin A</bold> (<bold>23</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Pseudomonas</italic> sp.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Pseudomonas syringae pv. Tomato</italic> DC3000 (4 &#x003bc;M); <italic toggle="yes">Staphylococcus aureus</italic> subsp. <italic toggle="yes">Aureus</italic> 5334R4 (2 &#x003bc;M), <italic toggle="yes">Bacillus cereus</italic> ATCC14579 (2 &#x003bc;M); <italic toggle="yes">Xanthromonas translucens</italic> pv. <italic toggle="yes">Graminis</italic> LMG587 (2 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Binding with lipoteichoic acids and forming pores in the bacterial membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-molecules-28-04183" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Malacidin A</bold> (<bold>24</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desert soil metagenome BGC heterologous expressed by <italic toggle="yes">Streptomyces albus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (0.16&#x02013;0.64 &#x003bc;<sc>M</sc>); <italic toggle="yes">S. aureus</italic> NRS146 (0.32&#x02013;0.64 &#x003bc;<sc>M</sc>); VRE (0.64&#x02013;1.6 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcium-dependent bacteria cell wall inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-molecules-28-04183" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Taromycin A</bold> (<bold>26</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Saccharomonospora</italic> sp. CNQ-490</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">With 50 &#x003bc;g ml<sup>&#x02212;1</sup> CaCl<sub>2</sub>: DapR MRSA A8817 (30.5 &#x003bc;M); DapS MRSA A8819 (1.89 &#x003bc;M); DapR VRE 447 (30.5 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcium-dependent bacteria membrane disruption</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-molecules-28-04183" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Teixobactin</bold> (<bold>28</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Eleftheria terrae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (0.2 &#x003bc;<sc>M</sc>); VRE (0.4 &#x003bc;<sc>M</sc>); penicillin-resistant <italic toggle="yes">Streptococcus pneumoniae</italic> (&#x02264;24 n<sc>M); </sc><italic toggle="yes">M. tuberculosis</italic> H37Rv (0.1 &#x003bc;<sc>M</sc>); <italic toggle="yes">Clostridium difficile</italic> (4 nM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds to lipid II and III, inhibits bacteria cell wall synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-molecules-28-04183" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Lugdunin</bold> (<bold>29</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus lugdunensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (1.92 &#x003bc;<sc>M</sc>); VRE (3.8 &#x003bc;<sc>M</sc>); <italic toggle="yes">S. aureus</italic> Mu50 (3.8 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-molecules-28-04183" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Macolacin</bold> (<bold>30</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Paenibacillus xylanexedens mac</italic> BGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antimicrobial-resistant <italic toggle="yes">Acinetobacter baumannii</italic> (1.7&#x02013;6.85 &#x003bc;<sc>M</sc>); colistin-resistant <italic toggle="yes">Neisseria gonorrhoeae</italic> (3.4 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds to lipid A of LPS and disrupts the bacteria cell membrane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-molecules-28-04183" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Humimycin A</bold> (<bold>32</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Rhodococcus equi</italic> BGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (7.25 &#x003bc;<sc>M</sc>); <italic toggle="yes">Streptococcus pneumoniae</italic> (3.6 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit bacteria cell wall synthesis by inhibiting peptidoglycan translocation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-28-04183" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Paenimucillin A</bold> (<bold>34</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Paenibacillus mucilaginosus</italic> K02 BGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Enterococcus faecium</italic> (2.5 &#x003bc;<sc>M</sc>); <italic toggle="yes">Staphylococcus aureus</italic> (9.8 &#x003bc;<sc>M</sc>); <italic toggle="yes">Acinetobacter baumannii</italic> (9.8 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May bind lipid II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-molecules-28-04183" ref-type="bibr">41</xref>,<xref rid="B42-molecules-28-04183" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Paenimucillins C</bold> (<bold>36</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Paenibacillus mucilaginosus</italic> K02 BGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multidrug-resistant <italic toggle="yes">Acinetobacter baumannii</italic> (0.3&#x02013;2.5 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bacteria cell membrane disruption</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-molecules-28-04183" ref-type="bibr">41</xref>,<xref rid="B42-molecules-28-04183" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>37</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Xenorhabdus nematophila</italic> BGC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">C. albicans</italic> (3.2 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-molecules-28-04183" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Di-alboflavusin A<sub>1</sub></bold> (<bold>38</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces alboflavus</italic> sp. 313</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA 113 (0.78 &#x003bc;<sc>M</sc>); MRSA 09L098 (0.63 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-molecules-28-04183" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Lactocillin</bold> (<bold>40</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lactobacillus paragasseri JV-V03</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic> (0.42 &#x003bc;<sc>M</sc>); <italic toggle="yes">Corynebacterium aurimucosum</italic> (0.42 &#x003bc;<sc>M</sc>); <italic toggle="yes">Streptococcus sobrinus</italic> (0.85 &#x003bc;<sc>M</sc>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-molecules-28-04183" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Lichenicidin</bold> (<bold>41</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus licheniformis</italic> D13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus megaterium</italic> (0.48 &#x003bc;M); <italic toggle="yes">Bacillus subtilis</italic> (0.96 &#x003bc;M); <italic toggle="yes">Micrococcus luteus</italic> (0.17 &#x003bc;M); <italic toggle="yes">Rhodococcus</italic> spp. (&#x0003e;2.56 &#x003bc;M); <italic toggle="yes">S. aureus</italic> (0.96 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-molecules-28-04183" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Thiomuracin</bold> (<bold>42</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Thermobispora bispora</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (0.18 &#x003bc;M); VRE <italic toggle="yes">E. faecium</italic> U503 (0.046 &#x003bc;M); <italic toggle="yes">B. anthracis</italic> str. Sterne (1.5 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits bacterial protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-molecules-28-04183" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Specialicin</bold> (<bold>43</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Streptomyces specialis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M. luteus</italic> (3.75 &#x003bc;M); IC<sub>50</sub> of 7.2 &#x003bc;M against HIV-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-molecules-28-04183" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Lassomycin</bold> (<bold>44</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Lentzia kentuckyensis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Mycobacterium tuberculosis</italic> (0.41&#x02013;1.65 &#x003bc;M); drug-resistant <italic toggle="yes">M. tuberculosis</italic> (0.21&#x02013;1.65 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits ATP-dependent protease of <italic toggle="yes">M. tuberculosis</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-molecules-28-04183" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Bottromycin</bold> A<sub>2</sub> (<bold>45</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. <italic toggle="yes">BC16019</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">MRSA</italic> (1.2 &#x003bc;M); <italic toggle="yes">VRE</italic> (&#x0003c;1.2 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits protein synthesis by blocking the binding site on the 50S&#x02005;ribosome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-molecules-28-04183" ref-type="bibr">53</xref>,<xref rid="B54-molecules-28-04183" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Citrocin</bold> (<bold>46</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Citrobacter pasteurii</italic> and <italic toggle="yes">Citrobacter braakii</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. coli</italic> O157:H7 strain TUV93-0 (16 &#x003bc;M); <italic toggle="yes">Salmonella enterica</italic> serovar <italic toggle="yes">Newport</italic> (1000 &#x003bc;M); <italic toggle="yes">Citrobacter</italic> clinical isolate (125 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-molecules-28-04183" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>TL19</bold> (<bold>48</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RiPP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetically produced</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDR <italic toggle="yes">E. faecium</italic> (0.9 to 15 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May bind to lipid II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-molecules-28-04183" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Phenaszentines C</bold> (<bold>61</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz/NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Xenorhabdus szentirmaii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Board spectrum of Gram-positive and -negative bacteria (MIC not available)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-molecules-28-04183" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><sub>D</sub>-alanylgriseoluteic acid</bold> (<bold>62</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz/NRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Pantoea agglomerans</italic> Eh1087</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Penicillin-resistant <italic toggle="yes">Streptococcus pneumoniae</italic> (1.4 &#x000b5;M); <italic toggle="yes">E. coli</italic> (2.8&#x02013;5.6 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces SOS response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-molecules-28-04183" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Diastaphenazine</bold> (<bold>64</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces diastaticus</italic> subsp. ardesiacus.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> (147 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-molecules-28-04183" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Streptophenazine C</bold> (<bold>71</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. HB202</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus subtilis</italic> (38 &#x000b5;M); <italic toggle="yes">Staphylococcus lentus</italic> (114 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-molecules-28-04183" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Streptophenazine H</bold> (<bold>76</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. HB202</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus subtilis</italic> (35 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-molecules-28-04183" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Streptophenazine Q</bold> (<bold>77</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz/NRP/PK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. CNB-091</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA TCH1516 (78 &#x000b5;M); Group A <italic toggle="yes">Streptococcus</italic> (4.9 &#x000b5;M); <italic toggle="yes">Acinetobacter baumannii</italic> 5075 (78 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-molecules-28-04183" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Clofazimine derivative</bold> (<bold>81</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organic synthesized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">multidrug-resistant <italic toggle="yes">M. tuberculosis</italic> (0.3 &#x000b5;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May release reactive oxygen species</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-molecules-28-04183" ref-type="bibr">75</xref>,<xref rid="B76-molecules-28-04183" ref-type="bibr">76</xref>,<xref rid="B77-molecules-28-04183" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>83</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organic synthesized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampicin-resistant <italic toggle="yes">M. tuberculosis</italic> (2.2 &#x003bc;M); <italic toggle="yes">M. tuberculosis</italic> H37Rv (2.2 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-molecules-28-04183" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>2-Br-1-OHPhz</bold> (<bold>85</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. CNS284</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (6.25 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-molecules-28-04183" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>2,4-diBr-1-OHPhz</bold> (<bold>86</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organic synthesized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (1.17 &#x003bc;M); MRSE (1.17 &#x003bc;M); VRE (6.25 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Causes iron starvation in MRSA biofilms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-molecules-28-04183" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>2,4-diBr-7-Cl-1-OHPhz</bold> (<bold>87</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phz</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organic synthesized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MRSA (0.04 &#x003bc;M); MRSE (0.10 &#x003bc;M); VRE (0.39 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Causes iron starvation in MRSA biofilms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-molecules-28-04183" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Benditerpenoic acid</bold> (<bold>90</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Streptomyces</italic> sp. CL12-4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">E. faecium</italic> (401&#x003bc;M); <italic toggle="yes">S. aureus</italic> (200 &#x003bc;M); MRSA (200 &#x003bc;M); MDR <italic toggle="yes">S. aureus</italic> (401 &#x003bc;M); <italic toggle="yes">B. subtilis</italic> (100 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-molecules-28-04183" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Sarcotrocheliol</bold> (<bold>91</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Sarcophyton. trocheliophorum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic> (1.53 &#x003bc;M); MRSA (3.06 &#x003bc;M); <italic toggle="yes">Acinetobacter</italic> spp. (3.06 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-molecules-28-04183" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cembrene-C</bold> (<bold>92</bold>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">S. trocheliophorum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Candida albicans</italic> (0.68 &#x003bc;M); <italic toggle="yes">Aspergillus flavus</italic> (0.68 &#x003bc;M)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-molecules-28-04183" ref-type="bibr">87</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Compound classes: PK, polyketide; NRP, nonribosomal peptide; RiPP, ribosomal synthesized post-translational modified peptide; Phz, phenazine; and TP, terpene. Pathogen abbreviations: MRSA, Methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>; MSSA, Methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic>; MRSE, Methicillin-resistant <italic toggle="yes">Staphylococcus epidermidis</italic>; VRE, Vancomycin-resistant <italic toggle="yes">Enterococcus</italic>; DapR, daptomycin resistant; DapS, daptomycin susceptible. Pharmacological potency evaluation: MICs, minimum inhibition concentrations, values were calculated to molar concentration based on compound mass spectrum data and/or compound structures provided in the literature; MBECs, minimum biofilm eradication concentration, values were provided in the literature.</p></fn></table-wrap-foot></table-wrap></sec></back></article>